Exploring novel methods to achieve systemic delivery of SMN for treatment of spinal muscular atrophy

Emily McFall

Thesis submitted to the
Faculty of Graduate and Postdoctoral Studies
in partial fulfilment of the requirements
for the Masters degree in Microbiology and Immunology

Department of Biochemistry, Microbiology, & Immunology

Faculty of Medicine

University of Ottawa

©Emily McFall, Ottawa, Canada 2014
Abstract

Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease caused by insufficient levels of the survival motor neuron protein (SMN), leading to progressive deterioration of α-motor neurons, onset of muscle atrophy and, in severe disease, death. We investigated whether reducing the size of Adenovirus (Ad) vectors, through use of a short fibre protein, could enhance delivery of a transgene to muscle and motor neurons after systemic delivery \textit{in vivo}. Unfortunately, the biodistribution of the smaller Ad vector was unaltered compared to wildtype Ad, with most of the virus localizing to the liver. However, we determined Ad-derived SMN was efficiently packaged into cellular exosomes, suggesting a novel approach to protein delivery. We showed that exosomes naturally contain SMN both \textit{in vitro} and \textit{in vivo} and that exosomes can be used to deliver SMN to recipient cells. Further testing is required to establish if SMN-containing exosomes can function as an SMA therapeutic.
Acknowledgements

I would like to thank my supervisor, Dr. Robin Parks, for allowing me to work on two interesting projects. For his support and encouragement in times of struggle as everything did end up fine. Lastly, for his trust in allowing me to set my own schedule and experiment designs all the while being available whenever aid was needed. I would also like to thank my TAC members Dr. Rashmi Kothary and Dr. Bernard Jasmin who not only helped guide me on my research projects but my career path. I would like to thank the Ontario government and the Canadian Institutes of Health Research for funding my research.

I would like to thank each member of the Parks lab for making my graduate experience fun and memorable. To Joe Burns for taking me to Disneyland and making me laugh and cringe with his lively comments. To Kalisa Campbell for the stories, giggles and whatever. To Carmen Wong for putting up with my repetitive stats questions but mostly for coming out dancing. To Natacha Provost and André Richard for offering help and always trying to interrupt the best of my results. To Briti Saha for staying positive and to Mélissa Geoffroy for expanding my French vocabulary. Lastly and most importantly to Kathy Poulin as I never would have got this far without your help, amazing knowledge of everything in the Parks lab and our combined math skills. Next I would like to thank members in other labs who helped in my training and provided support Dr. Lyndsay Murray, Dr. Justin Boyer, Chantal Mazerolle, Dr. Erin Bassett, John Lunde, Dr. Dylan Burger, the animal care facility, in particular Kim and Eileen, and lastly my close friend Faduma Jama.

Finally I would like to thank my extensive editing team Joe, Carmen, André, Natacha, Kristen Marcellus, Yue Fainaru and Sruthi Kalyanasundaram. I would like to thank Scott Nichols who stood by me through the good days and the grumpy ones and lastly my parents who listened to the stories and provided all the support in the world.
Contributions

I would like to acknowledge both Dr. Robin Parks and Kathy Poulin who created and purified all the viruses used in this study.
Table of Contents

Abstract ii
Acknowledgements iii
Contributions iv
Table of Content v
List of Abbreviations vii
List of Figures ix
List of Tables x

1 Chapter 1: Background 1
1.1 Spinal Muscular Atrophy 1
   a. What is SMA? 1
   b. SMN genes 1
   c. Disease pathogenesis 2
   d. SMN protein and function 7
   e. Animal models 9
   f. Current treatments 10
1.2 Adenovirus 13
   a. Adenovirus background 13
   b. Fiber and retargeting 13
   c. Adenovirus vectors in gene therapy 17
1.3 Exosomes 19
   a. Exosome discovery 19
   b. Exosome formation and release 19
   c. Exosome entrance 23
   d. Exosome markers 24
   e. Exosome functions 25
   f. Exosome therapeutics 26
1.4 Rationale 28
1.5 Hypothesis 28
1.6 Objectives 29

2 Chapter 2: Methods and Materials 30
2.1 Cell culture 30
2.2 Cloning and Nucleofection 30
2.3 Generation and propagation of viruses 30
2.4 Particle counts 31
2.5 In vitro infections 31
2.6 Trichloroacetic acid media precipitation 32
2.7 In vivo infections 32
2.8 Tissue homogenization 33
2.9 Tissue sectioning 33
2.10 β-galactosidase staining 34
2.11 Exosome collection 34
2.12 Analysis of exosome-mediated delivery of protein to cells 35
2.13 Chemiluminescent β-galactosidase assay 35
3 Chapter 3: Reduced virion size does not enhance viral distribution in vivo

3.1 Introduction

3.2 Results
   a. Ad vectors are able to infect both motor neurons and muscle cells in vitro
   b. Ad vectors predominately localize to the liver and the site of injection
   c. Increased exposure periods did not result in enhanced infection in muscle tissue or retrograde transport to motor neurons

3.3 Discussion
   a. Overview
   b. Ad localizes predominantly to the liver
   c. Muscle infection is not enhanced through fiber modifications
   d. Spinal cord infection is detectable in the α-motor neurons

3.5 Conclusions

4 Chapter 4: Exosome transport of SMN

4.1 Introduction

4.2 Results
   a. SMN is present in exosomes
   b. Exosomes associate with recipient cells
   c. SMN is found in exosomes isolated from mouse serum
   d. Virally-derived β-gal can be loaded into exosomes in vivo
   e. Virally-derived SMN is undetectable in serum exosomes with anti-Flag

4.3 Discussion
   a. Overview
   b. Microparticle contamination
   c. Exosome yield
   d. Exosome markers
   e. SMN containing exosomes in vitro
   f. Exosome-mediated delivery of protein to recipient cells
   g. Detection of virus derived SMN in vivo

4.5 Conclusions

5 Chapter 5: Overview of SMA treatments

5.1 Summary

5.2 Future directions

5.3 Conclusions

6 References

7 Appendix 1 – Chemicals and Reagents

8 Appendix 2 – Chapter 3 manuscript published in Virology

9 Curriculum vitae
## List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>293</td>
<td>Human embryonic kidney cells</td>
</tr>
<tr>
<td>β-gal</td>
<td>β-galactosidase</td>
</tr>
<tr>
<td>A549</td>
<td>Adenocarcinomic human alveolar basal epithelial cells</td>
</tr>
<tr>
<td>A549::SMN</td>
<td>A549 cells with over expression of Flag-SMN through hygromycin selection</td>
</tr>
<tr>
<td>Ad</td>
<td>Adenovirus</td>
</tr>
<tr>
<td>Ad5</td>
<td>Adenovirus serotype 5, (Ad5 ΔE1/ΔE3 is considered control Ad for this thesis)</td>
</tr>
<tr>
<td>ASO</td>
<td>Antisense oligonucleotides</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>C2C12</td>
<td>Mouse myoblast C2C12 cells</td>
</tr>
<tr>
<td>CAR</td>
<td>Coxsackievirus adenovirus receptor</td>
</tr>
<tr>
<td>CARM1</td>
<td>Co-activator-associated arginine methyltransferase 1</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s medium</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>E1</td>
<td>Early region 1</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetraacetic acid</td>
</tr>
<tr>
<td>ESCRT</td>
<td>Endosomal sorting complex required for transport</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal bovine serum</td>
</tr>
<tr>
<td>Flag</td>
<td>Epitope tag DYKDDDDK</td>
</tr>
<tr>
<td>HUVEC</td>
<td>Human umbilical vein endothelial cells</td>
</tr>
<tr>
<td>Hpi</td>
<td>Hours post infection</td>
</tr>
<tr>
<td>ILV</td>
<td>Intraluminal vesicles</td>
</tr>
<tr>
<td>IP</td>
<td>Intraperitoneal</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>kb</td>
<td>Kilobases</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodaltons</td>
</tr>
<tr>
<td>MDA</td>
<td>Megadaltons</td>
</tr>
<tr>
<td>LD</td>
<td>Laemmli loading dye</td>
</tr>
<tr>
<td>MEM</td>
<td>Minimum essential medium</td>
</tr>
<tr>
<td>MOI</td>
<td>Multiplicity of infection</td>
</tr>
<tr>
<td>MNJ</td>
<td>Cholinergic motor neuron cells</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger RNA</td>
</tr>
<tr>
<td>MVB</td>
<td>Multivesicular bodies</td>
</tr>
<tr>
<td>N3S</td>
<td>293N3S cells</td>
</tr>
<tr>
<td>NMJ</td>
<td>Neuromuscular junction</td>
</tr>
<tr>
<td>pA</td>
<td>Polyadenylation signal</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PFA</td>
<td>Paraformaldehyde</td>
</tr>
<tr>
<td>RGD loop</td>
<td>Amino acid sequence Arg-Gly-Asp</td>
</tr>
<tr>
<td>RIPA</td>
<td>Radioimmunoprecipitation assay buffer</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>rRNA</td>
<td>Ribosomal RNA</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulfate</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulfate polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>shRNA</td>
<td>Short hairpin RNA</td>
</tr>
<tr>
<td>siRNA</td>
<td>Short interfering RNA</td>
</tr>
<tr>
<td>SMA</td>
<td>Spinal muscular atrophy</td>
</tr>
<tr>
<td>SMN</td>
<td>Survival motor neuron</td>
</tr>
<tr>
<td>SMNΔ7</td>
<td>Truncated SMN protein produced from SMN2</td>
</tr>
<tr>
<td>SMN1</td>
<td>Survival motor neuron 1 gene (telomeric)</td>
</tr>
<tr>
<td>SMN2</td>
<td>Survival motor neuron 2 gene (centromeric)</td>
</tr>
<tr>
<td>snRNP</td>
<td>Small nuclear ribonucleic particle</td>
</tr>
<tr>
<td>TA</td>
<td>Tibialis anterior</td>
</tr>
<tr>
<td>TBST</td>
<td>Tris buffered saline tween</td>
</tr>
<tr>
<td>TCA</td>
<td>Trichloroacetic acid</td>
</tr>
<tr>
<td>X-gal</td>
<td>5-bromo-4-chloro-3-indolyl-β-D-galatopyranoside</td>
</tr>
</tbody>
</table>
List of Figures

Figure 1.1 – Schematic of SMN1 and SMN2 3
Figure 1.2 – Fiber structure and domains 14
Figure 1.3 – Exosome formation and release 20

Figure 3.1 – Viral constructs 40
Figure 3.2 – Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ differ in fiber size 43
Figure 3.3 – Infection of Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in established cell lines derived from different tissues 45
Figure 3.4 – Analysis of transgene expression from Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in TA muscle and liver 48
Figure 3.5 – Histological analysis of β-gal expression in the TA muscle, spinal cord and diaphragm of treated animals 51
Figure 3.6 – Analysis of Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in TA muscle and liver with extended exposure periods 54
Figure 3.7 – Histological analysis of β-gal expression in the TA muscle after extended exposure periods 57
Figure 3.8 – Immunofluorescence of TA muscles by β-gal and α-laminin 60
Figure 3.9 – Immunofluorescence analysis of motor neurons and histological analysis of β-gal expression 63

Figure 4.1 – Analysis of SMN levels in cells and media for cell treated with Ad-SP-SMN or Ad-SMN 71
Figure 4.2 – Native SMN is detectable in media following TCA precipitation 74
Figure 4.3 – Size of harvested exosomes and detection with various markers 77
Figure 4.4 – SMN is present in microvesicles, including exosomes, from various cell lines 80
Figure 4.5 – SMN expression can be enhanced in exosomes using an SMN-over expressing cell line 82
Figure 4.6 – A549::SMN cells express Flag-tagged SMN 84
Figure 4.7 – The level of SMN protein is enhanced in exosomes isolated from Ad-SMN infected cells 86
Figure 4.8 – Exosomes associate with A549 recipient cells 89
Figure 4.9 – Isolation of serum-derived exosomes 92
Figure 4.10 – Endogenous SMN is detectable in tissues and serum 94
Figure 4.11 – Virally produced β-gal is detectable in both cellular- and serum-derived exosomes 97
Figure 4.12 – In vivo Ad-SMN injection results in elevated SMN levels in the liver but not in serum-derived exosomes 100
Figure 4.13 – Myc and his tags contained on Ad-SMN-myc-his are not detectable in serum exosomes 103
List of Tables

Table 1.1 – Clinical classifications of SMA 6
Table 2.1 – Primary antibodies 38
Table 3.1 – Area of TA muscle expressing β-gal following TA injection 59
Chapter 1 - Background

1.1 Spinal Muscular Atrophy

1.1.a What is SMA?

Spinal muscular atrophy (SMA) occurs in approximately 1 in 6,000 live births making it the most common inherited neurodegenerative disease leading to infant mortality [13,37]. SMA is an autosomal recessive disorder with a carrier frequency of approximately 1 in 50 in America [80, 83]. The disease presents as progressive deterioration of skeletal muscle and α-motor neurons in the anterior horn of the spinal cord [37]. SMA results in weakness in the proximal limbs, hypotonia, trunk paralysis and impairment of the ability to breathe leading to suffocation and death [37].

1.1.b SMN genes

SMA is caused by a deficiency in the survival motor neuron (SMN) protein due to the inactivation of the \textit{SMN1} gene [56]. In 95\% of cases, inactivation occurs through a homozygous deletion of the \textit{SMN1} gene while the other 5\% of cases display non-synonymous point mutations [88]. Thus far, it appears humans are the only species to have undergone a gene duplication event of the 500 kb \textit{SMN1} element resulting in an additional copy of the gene, \textit{SMN2} [56]. Both SMN genes are found on chromosome 5q13.2 with \textit{SMN1} at the telomeric position [56]. Over the 32 kb region of the SMN gene, there is 99\% homology between \textit{SMN1} and \textit{SMN2}, with quasi-identical promoter sequences suggesting equal transcription levels [76,27]. \textit{SMN2} differs from \textit{SMN1} in only 5 point mutations: 3 intronic sites (intron 6 position -45, intron 7 position +100, intron 7 position +214) and 2 exonic sites (exon 7 position +6, exon 8 position +245) [64]. All of these mutations are synonymous, resulting in equivalent full length proteins (Figure 1.1) [64]. However,
extensive research has shown, the cytosine to thymidine mutation within exon 7 of \textit{SMN2} results in an alternate splicing event and the loss of exon 7 [64]. This altered splicing produces a truncated protein, SMN\(\Delta\)7 [63]. SMN\(\Delta\)7 lacks the normal 16 carboxyl amino acids; however, the junction of exon 6 to exon 8 results in SMN\(\Delta\)7 acquiring 4 unique terminal amino acids [9]. It is thought that this cytosine to thymidine mutation in \textit{SMN2} may lead to alternate splicing through the disruption of an exon-splicing enhancer site which consequently promotes the exclusion of exon 7 [63]. However, the exact exon-splicing enhancer site affected by the point mutation has not yet been identified. As such, alternate theories exist involving the formation of other \textit{cis} elements or improper mRNA secondary structures to explain this splicing event [75]. Since SMA patients lack \textit{SMN1}, they rely solely on the SMN protein produced from the \textit{SMN2} gene. Unfortunately \textit{SMN2} is correctly spliced, producing functional full length SMN, only 10-15\% of the time [63]. This reduced yield of functional SMN is insufficient to compensate for the loss of \textit{SMN1}, resulting in a disease state.

1.1.c \textbf{Disease pathogenesis}

SMA patients can be divided into four different levels of disease severity. Type I, also known as Werdnig-Hoffman disease, is an extremely severe form of SMA and unfortunately the most common [55]. Type I SMA patients are diagnosed shortly after birth, never gain the ability to sit and generally die before the age of two [92]. Type II patients are diagnosed between 6-18 months of age and have a life expectancy of 10-40 years [92]. These patients may be able to sit independently but never walk [92]. Type III SMA, also known as Kugelberg-Welander disease, is diagnosed at later stages in childhood [55]. Patients with Type III SMA have normal life expectancy and are physically mobile, but not all symptoms
Due to a recent duplication event, humans encode two SMN genes on chromosome 5. $\textit{SMN1}$ (telomeric) and $\textit{SMN2}$ (centromeric) differ in only five synonymous point mutations resulting in equivalent full length proteins. However, the cytosine to thymidine mutation at position 6 within exon 7 (*) results in alternate splicing of $\textit{SMN2}$ through the exclusion of exon 7. Figure modified from Mittal B. [74].
are alleviated [92]. Type IV SMA is the only type with an adult onset; although these patients live with proximal limb muscle atrophies, their symptoms are significantly reduced and they are often never diagnosed as SMA patients [92]. Some researchers and families recognize a fifth level of SMA severity, Type 0. In patients with Type 0 SMA there is an inadequate level of SMN to sustain life and the fetus is lost prior to birth or soon afterwards (Table 1.1) [92].

SMA severity is proportional to the copy number of SMN2 [56, 29]. Increased copy number of SMN2 results in an enhanced amount of full-length SMN which in turn alleviates disease pathogenesis [57]. In general, Type I patients have 1-2 copies of SMN2, Type II patients have 3 copies, Type III patients have 3-5 copies of SMN2 and the SMN2 copy number in Type IV patients is unclear but thought to be 4-6 [29]. The loss of both SMN1 and SMN2 is embryonic lethal, indicating the essential need for the SMN protein [80]. Genetic screening for parents of affected children or siblings can be done to determine SMN2 copy number for a more accurate risk assessment [73].

Research involving SMA mouse models (discussed below) have led to the discovery of SMN thresholds, which are believed to be relevant to humans as well [9]. A protein threshold level implies that more protein is transcribed than needed for proper functioning of the cell. Evidence for a threshold level of SMN was determined through SMN knockdown experiments with shRNAs, where a reduction to 20% wildtype SMN levels resulted in no morphological change in HeLa cells [120]. As such, it is concluded that not all of the SMN transcribed by SMN1 is needed for proper functioning. In conjunction with this, the amount of SMN required from SMN2 does not need to be equivalent to that of SMN1, but simply over the threshold level for proper functioning. Since Type IV patients have between 4 and 6 copies of SMN2 the human SMN threshold level must be greater than the
### Table 1.1 Clinical classifications of SMA

<table>
<thead>
<tr>
<th>Type</th>
<th>Age of onset</th>
<th>Physical characteristics</th>
<th>Life Expectancy</th>
<th>SMN2 copy number</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>prenatal</td>
<td>Fetus displays reduced movement</td>
<td>Fatal at birth</td>
<td>unknown</td>
</tr>
<tr>
<td>I</td>
<td>&lt; 6 months</td>
<td>Children are never able to sit</td>
<td>2 years</td>
<td>1-2</td>
</tr>
<tr>
<td>II</td>
<td>6 - 18 months</td>
<td>Children can sit independently</td>
<td>10-40 years</td>
<td>3</td>
</tr>
<tr>
<td>III</td>
<td>&gt;18 months</td>
<td>Children can walk independently</td>
<td>Normal</td>
<td>3-5</td>
</tr>
<tr>
<td>IV</td>
<td>Adulthood</td>
<td>Patients display mild muscle weakness</td>
<td>Normal</td>
<td>4-6</td>
</tr>
</tbody>
</table>

Table modified from Russman [92]
amount of full-length SMN yielded by 6 copies of $SMN_2$. Assuming equal transcription rates between $SMN_1$ and $SMN_2$ due to their quasi-identical promoter sequences and assuming $SMN_2$ produces full length SMN protein 10% of the time, 6 copies of $SMN_2$ produces 30% of the total SMN protein found under normal conditions. This would suggest that the human SMN threshold level is higher then 30%.

1.1.d SMN protein and function

SMN is a 38 kDa, 294 amino acid protein which is ubiquitously expressed in multicellular organisms [56, 49]. The protein is found in both the cytoplasm and the nucleus [61]. In the cytoplasm, SMN can be detected within the trans-Golgi network and interacts with various proteins [106]. Within the nucleus SMN is found in gemini of coiled bodies or gems for short [57]. These gems co-localize with coilin in Cajal bodies [118]. SMN self-associates and interacts with Gemin 2-8 to form the SMN complex [37]. This SMN complex is also known to form close associations with UNR-interacting protein [61, 17]. Self-association of SMN and its participation in the SMN complex increases the protein's overall stability. Burnett et al showed that exons 2, 6 and 7 are important in self-association and therefore play a role in SMN stability [13]. SMNΔ7 is also able to associate with full length SMN [13]. However, the loss of exon 7 in SMNΔ7 significantly reduces its half-life to only two hours compared to over four hours for full length SMN [13].

The varied functions of SMN are being investigated extensively to determine the causal factor leading to the disease state specifically in motor neurons. SMN is best known for its strict requirement in the formation of the Sm protein ring on small nuclear ribonucleic particles (snRNPs), a necessary component of spliceosomes [61]. Surprisingly, it was found that SMN deficiency does not result in a uniform reduction in snRNPs, but some genes and
some cell types appear preferentially reduced [120]. This finding may suggest a possible reason for why an ubiquitous expressed protein results specifically in a motor-neuron disease. Recent experiments have identified a potential gene, stasimon, which is expressed in neurons and affected by snRNP splicing [66]. Stasimon is required for normal synaptic transmission of motor neurons and its addition in SMA animal models results in significant phenotypic improvement [66] Unfortunately, stasimon deficiency cannot account for all defects observed in SMA animal models. For example Lotti et al. showed that although the addition of stasimon improved defects in the neuromuscular junctions (NMJ) in SMN-deficient Drosophila stasimon was unable to correct for irregular locomotion and rhythmic motor activity, suggesting a more complex mechanism is occurring [66].

SMN is also thought to be involved in gene expression and translation [43]. Sanchez et al. observed SMN co-fractioned with polyribosomes suggesting a physical association with the translational machinery [43]. They went on to show that SMN is not required for polyribosome assembly and therefore SMN alters translation of only a subset of mRNAs, including CARM1 (co-activator-associated arginine methyltransferase 1) [43]. As observed with SMN's function in splicing, the limited number of mRNA affected may lead to a cell specific effect and explain why deterioration in SMA occurs mainly in the motor neurons.

The NMJ appear to form properly in SMA models but become denervated at early stages of disease development [60], suggesting a role of SMN in maintaining synapse formation [60]. Ling et al. showed that the NMJs affected depended on a combination of determinants, although head and trunk muscles proved to be key targets for denervation [60]. Additional studies showed that following damage, SMA murine models demonstrated decreased NMJ remodeling [78]. Possibly related to the defects in the NMJ, Ting et al. showed decreased SMN levels resulted in reduced size of neuronal growth cones [106]. It is
known that SMN functions with hnRNP to localize β-actin mRNA in these growth cones [90]. Decreases in growth cone size as a result of low SMN levels may affect proteins which are enriched in growth cones, like β-actin [90].

Although it is thought that SMN has a specific neuronal function or neurons are more highly affected by SMN activity, SMN is necessary for survival of all cell types [49]. As such, some peripheral tissues are also affected in SMA. Peripheral tissues appear to have a lower SMN threshold level than motor neurons and therefore maintain proper functioning in mild cases of SMA [91]. For instance, there is a relationship between Type I SMA and congenital heart failure [91]. Similarly, Martinez-Hernandez et al showed that murine muscle tissue in SMA models differs from that of wild-type mice in terms of growth, behaviour and architecture [69]. Overall it remains unclear which, if any, of these functions lead to the disease progression observed in SMA.

1.1.e Animal models

The SMN gene is high conserved across species; however, only humans are known to have undergone a gene duplication event and therefore all other animals have only one gene, smn [65]. This smn gene functions equivalently to SMN1 in humans and the lack of smn is embryonic lethal [5]. As such, SMA does not occur naturally in animals. In order to study SMA, animal models with altered levels of SMN protein were created to reflect the different levels of disease severity; species include zebrafish, Drosophila, cats and murine models, where murine models remain the most common [65, 26]. The creation of murine SMA models involved the introduction of various combinations of both human and murine SMN genes to achieve varying levels of the protein resulting in differing rates of disease progression [5]. Removal of one murine smn gene, smn+/−, or the addition of four copies of
human SMN2 in a null smn background resulted in a normal life span with the latter presenting peripheral necrosis of the tail and ears [5]. This indicates that the murine threshold level is just over four copies of SMN2. Reducing the SMN2 copy number by half resulted in a severe case of SMA, representative of Type I SMA patients [5]. In this murine model, smn-/--;SMN2, with only two copies of SMN2, mice have a life expectancy of 6-7 days and exhibit decreased muscle movements, decreased size and develop tail and ear necrosis [54]. However, life expectancy can be increased to 14 days with the addition of a gene encoding the truncated SMNΔ7 protein [54]. This mouse model, smn-/--;SMN2;Δ7, indicates that the miss-spliced protein product from SMN2 may still contribute to SMN function. Lastly, Bowerman et al created a mild murine model, SMN2B/−, from a C57BL/6 background to reflect Type III SMA patients [8]. Bowerman and colleagues inserted a three nucleotide substitution in the exon-splicing enhancer site of exon 7 within the smn gene [8]. This resulted in alternate splicing of the smn gene similar to that of human SMN2 and as such reflects the splicing defect in SMA [8, 5]. These mice have a longer life expectancy of 28 days with the disease phenotype presenting itself at post-natal day 10 as decreased muscle strength, decreased size and tail necrosis [8].

1.1.f Current treatments

There is no cure for SMA and most treatment options involve alleviating symptoms [80]. Research is ongoing to determine methods to increase SMN levels in SMA patients, thereby preventing disease progression. There are many proposals under investigation including (i) enhancing SMN stability, (ii) correction of SMN2 splicing and (iii) introduction of corrected SMN genes [80].
The small amount of full length SMN produced in SMA patients can be targeted for stability therapeutics. Stability of SMN can be enhanced through phosphorylation as demonstrated by Burney et al who showed forskolin stimulates PKA phosphorylation and in turn increases SMN stability [13]. Enhanced stability of SMNΔ7 is also being explored as findings in murine models suggest that SMNΔ7 may be partially functional [54]. Improved SMNΔ7 stability can be achieved by translational read-through to prevent termination at the initial stop codon, in this way increasing the size of the SMNΔ7 protein and consequently stability [42]. Aminoglycoside antibiotics, some of which are FDA approved, have been shown to bind ribosomes allowing for translational read through [42]. Unfortunately, the compound tested by Heier and Didonato, G418, showed increases in motor function in vivo but presented significant toxicity preventing any conclusions involving improvement of weight or survival time [42].

SMN levels can be enhanced through splicing correction using small molecules, antisense oligonucleotides (ASO) or trans-splicing mRNA. ASOs block Intronic Splicing Silencers near exon 7 increasing the amount of full length SMN transcribed [80]. Studies have shown ASOs are able to successfully enhance inclusion of exon 7, increase the number of gems and display promising long term results [94, 44]. ASOs can also spread systemically, however maximum inclusion of exon 7 in the spinal cord and brain are observed with direct central nervous system (CNS) injections [44]. Small molecules can be used for splicing correction or to enhance SMN transcription, for example histone decetylase inhibitors (Trichstatin A and Valproic acid) and β-adrenergic agonist (salbutamol) [5, 81]. Some of these small molecules are approved by the FDA for treatment for other disorders and therefore could function as SMA therapeutics in the near future [10]. Unfortunately, double bind clinical trials suggest some of these drugs may be more efficient at increasing
SMN levels in murine models than humans or the observed benefits may be partially due to the placebo effect [19, 81]. Another avenue to correct SMN2 splicing is through trans-splicing mRNA. Trans-splicing requires two different mRNAs, the endogenous mutated mRNA and exogenous corrected mRNA [21]. Coady and Lorson have shown that trans-splicing is beneficial in the CNS and distal tissues through increases in snRNP assembly and longer life span following intracerebral-ventricular injections [21].

Lastly, introduction of the SMN gene can be achieved through administration of viral vectors or stem cells [80]. Pluripotent stem cells, from Type I SMA patients, were corrected by converting the key point mutation in SMN2 to reflect the sequence of SMN1 [22]. These cells were differentiated into motor neurons and experiments have demonstrated both increased size of motor neurons and number of gems [22]. Preliminary results with AAV viral vectors resulted in widespread transduction of the SMN gene, demonstrated enhanced survival times and improvements in physical health [6].

Research remains underway to determine the best treatment to delay disease progression, however all methods are associated with risks and challenges. Also being developed is a biomarker panel for the plasma proteins in SMA patients, the goal being to determine disease severity, predict motor function and evaluate therapeutics through biomarkers [48]. Research continues in labs across the world and conferences are held annually to share new knowledge about SMA.
1.2  Adenovirus

1.2.a  Adenovirus background

Adenovirus (Ad) is a double stranded DNA virus with a 36 kb genome [110]. Replication occurs within the nucleus and the genome is packaged into a ~950 Å naked icosahedral capsid for a total weight of 150 MDa [68]. Ad has nine capsid proteins, three major: hexon (pII), penton (pIII) and fiber (pIV), and five minor: pVI, pVIII, pIIIa, pIVa2 and pIX [110]. There are over 50 serotypes of Ad which can be divided into six different subtypes [110]. Although all serotypes have similar structural and genomic characteristics they can differ in their interactions with host cells [68].

Ad has been greatly studied over the past 60 years and has helped in the discovery of host-virus interactions and eukaryotic processes such as alternate splicing and apoptosis [68]. Ad is able to infect a variety of species including humans, and can lead to respiratory, gastrointestinal and eye infections [68]. Fortunately, most infections remain subclinical unless in an immunocompromised person [68].

1.2.b  Fiber and retargeting

Fiber, one of the major capsid proteins, functions in Ad attachment to host cells [68]. The protein is projected from the capsid surface in trimers from a penton base at each of the 12 vertices [72]. Fiber is composed of a tail, shaft and knob (Figure 1.2) [72]. Ad attachment and uptake into host cells is a two step process: first the fiber knob interacts with the cellular coxsackie-adenovirus receptor (CAR) [68]. CAR is a member of the immunoglobulin family and is expressed on most cell types [115]. CAR functions as the primary receptor for most Ad serotypes including Ad5 [68]. Once the virus is attached to the host cell, fiber’s flexible shaft is able to bend, decreasing the distance between the virus and the cell [68]. This allows
Figure 1.2 Fiber structure and domains. Fiber is projected in trimers from a penton base located at each of the adenovirus capsid vertices. The fiber protein has three domains, an N-terminal tail buried within the penton base, a flexible shaft and a C-terminal knob involved in cellular binding. Figure modified from Medina-Kauwe [72].
for the second step of viral entry where the RGD loop (Arg-Gly-Asp) in the penton based interacts with cellular αv integrins to stimulate endocytosis [68].

It is well established that Ad predominately localizes to the liver after systemic delivery [47]. This event occurs not only due to the physical structure of the liver but the scavenging Kupffer cells which reside there [84]. Due to this high liver tropism there is ongoing research to explore Ad retargeting. A number of capsid proteins including: hexon, pIX, penton and fiber have been manipulated in an attempt to alter Ad targeting [84]. These protein modifications are achieved through the addition of targeting ligands via covalent, non-covalent or genetic modifications [84]. These ligands can increase specificity towards cell specific receptors or decrease specificity for CAR, either way altering Ad tropism. Bramson et al showed that the addition of poly-lysine residues to the Ad5 H-I loop within the fiber knob enhanced Ad muscle infection in vivo through increasing specificity to heparan sulphate proteoglycans [11]. Heparan sulphate proteoglycans are highly sulphated carbohydrates that can mediate CAR-independent attachment for some Ad serotypes, including Ad5 [119]. It is also possible to alter targeting by combining different Ad serotypes to form chimeric vectors. The small differences in Ad serotypes can result in different host-viral interactions [68]. For instance Ad35 is known to interact mainly with CD46 not CAR, while Ad9 is thought to bind two different primary receptors, one of which is CAR [119, 98]. Shayakhmetov et al created a chimeric vector (Ad5/9) to observe differences in receptor binding [98]. Based on Shayakhmetov results, it was concluded that two factors play a major role in Ad internalization i) knob specificity to the primary receptor and ii) the length of the shaft hence the distance between the virus and the cell membrane [98]. Overall, differences in fiber knob and shaft domains as well as additional targeting ligands can affect receptor attachment and therefore alter Ad targeting.
1.2.c Adenovirus vectors in gene therapy

Ad has great potential as a viral vector for gene therapy [68]. Ad-based vectors are created through the removal of essential viral genes, mainly early region 1 (E1), to ensure the virus is no longer replication competent [23]. Desired therapeutic genes can then be inserted into the viral genome. Ad has many advantages, in terms of gene therapy, over other vector systems such as: large cloning capacity, remaining primarily episomal and a relatively good safety profile [116]. In 1993 the first human study was done using a recombinant Ad to treat cystic fibrosis [23]. Since that time clinical trials have been initiated for a variety of other diseases with varying degrees of success [116]. Researchers have been looking into means of improving Ad as a viral vector, mainly through Ad retargeting, discussed above. Presently Ad is the leading platform for human clinical trials, representing approximately 23% of viral vectors in 2012 [32]. There are currently two approved therapeutics bases on Ad viral vectors, both for the treatment of cancer and only approved in China [116].

One drawback to Ad as a viral vector is its ability to activate the immune system as Ad epitopes are easily recognized [23]. Work to address this issue has taken place through two methods, first when the immune response becomes too robust to a given Ad vector, the viral backbone can be replaced with an alternate Ad serotype [23]. Second, reducing the number of genes which encode viral proteins within a vector decreases the immune response. As such, several generations of Ad have been developed with differing degree of attenuation [23]. First generation Ad, the most common, has the removal of only the essential E1 gene allowing for a cloning capacity of 4.7 kb [82]. In comparison helper dependent Ad has all viral genes removed allowing for a 37 kb cloning capacity [82]. The duration of expression from a vector in vivo varies depending on the immune response [82]. Current studies have shown that helper dependent Ad can persist for over 7 years in non-human primates with
high levels of gene transduction [12].
1.3  **Exosomes**

1.3.a  **Exosome discovery**

During normal conditions, as well as in states of distress, cells release microvesicles to carry out various cellular functions [112]. Different forms of these free-floating microvesicles are characterized by both size and cellular site of origin; however there is some overlap [112]. For example, microparticles are 100-1000 nm in size and formed through external budding of the plasma membrane, while apoptotic bodies are over 1 μm and formed during cellular breakdown [101, 99]. In 1983, Johnstone’s team studied small vesicles released from reticulocytes during their study of the transferrin receptor [112]. Johnstone defined these vesicles as exosomes based on the term described two years earlier by Trams et al [107]. Exosomes represent the third major type of microvesicles released from cells, with a diameter of only 30-100 nm and a cup-shaped morphology [71, 62].

1.3.b  **Exosome formation and release**

Unlike other microvesicles such as apoptotic bodies or microparticles, exosomes do not bud from the plasma membrane [62]. Instead exosomes originate from endosomes [62]. Endosomes can undergo a series of internal budding events to morph into multivesicular bodies (MVB) [111, 38]. The vesicles enclosed within the MVB are intraluminal vesicles (ILV), which contain both membrane and cytosolic proteins [104]. ILV are structured with an interior cytosolic bilayer, an exposed lumen membrane and an overall negative charge [104, 84]. As the MVB develops it can progress through different paths (Figure 1.3) [62]. The MVB can merge with a lysosome where the MVB and its contents will be degraded, or the MVB can merge with the plasma membrane resulting in release of the ILV [62, 111]. Once these vesicles are released into the extracellular matrix they are termed exosomes [62].
Figure 1.3 Exosome formation and release. Endosomes which undergo a series of internal budding are referred to as multivesicular bodies (MVB). Membrane proteins and cytosolic proteins can be captured during budding and be contained in these intraluminal vesicles (ILV). The MVB can either merge with a lysosome leading to degradation or fuse with the plasma membrane to release all ILV, now termed exosomes.
Some researchers believe there may be different populations of MVB which progress through specific pathways [62]. Trends have been observed that ILV high in phosphatidylinositol-3-phosphate, Rab7 and ubiquitinated proteins are processed by lysosomes while ILV high in ceramide, Rab11, Rab27 and cholesterol are released as exosomes [62, 99, 109].

Exosomes are estimated to be able to encompass 100 proteins and net 10,000 nucleotides [70]. Cytosolic and membrane proteins can be triggered for exosome packaging through signalling-induced ubiquitination [3]. Surprisingly cytosolic proteins (i.e. tubulin and SOD1), which lack any signal peptides, can also be found within exosomes due to the internal budding process during exosome formation [104, 33]. The method of ‘sorting’ proteins, mRNAs and microRNAs into exosomes is currently unknown; however studies have shown that some proteins are packaged at a higher rate in different stress conditions [58]. Similarly, the RNA contained in exosomes may represent only a sub-set of the RNAs expressed in the donor cell suggesting, exosomes are loaded with specific RNAs [108]. In fact, some microRNA and mRNA seem to be exclusively packaged into exosomes as they are found at much higher concentrations than that of the donor cell [108].

In the last several years, significant progress has been made in determining the mechanism involved in exosome release. Different cell types and cells at different stages of development are thought to vary in the amount of exosomes produced [2]. Release occurs in both a constitutive and regulated manner, where release can be altered through stress factors and stimulation signals [95, 62]. Studies have shown the importance of endosomal sorting complex required for transport (ESCRT) during exosome formation, particularly ILV formation [62]. ALIX a component of the ESCRT machinery is known to interact with syndecans through the adaptor protein, syntenin, which is required for proper budding and
ILV cleavage [3]. Kosaka et al demonstrated that exosome release is not dependent on ESCRT machinery but is dependent on ceramide [52]. Inhibiting ceramide biosynthesis, through down-regulation of neutral sphingomyelinase 2, has been directly shown to decreases exosome budding [52, 51]. Other components such as calcium levels and protein cross-linking or protein clustering also play a role in the rate of exosome release [58, 53, 111]. Carayon et al suggest that exosome packaging is a combination of pathways that work simultaneously or vary in dominance depending on cell type and level of cellular maturation [16].

1.3.c Exosome entrance

Much of the exosome field focuses on immune cells and the functions of immune generated exosomes. For this reason information on exosome entrance in immune cells is far better understood than in other cells types [62]. Exosome entrance occurs through fusion or receptor mediated endocytosis [70]. Fusion of exosomes to a cellular membrane appears to be lipid-dependent and results in the immediate transfer of membrane proteins [62, 70]. Endocytosis can occur through receptor/ligand mediated interactions [20] which implies cell specific communication [108]. Receptor mediated endocytosis requires the participation of the recipient cell’s cytoskeleton and is affected by both temperature and calcium levels [77]. Some receptors involved in exosome attachment include: PS, CD11a, CD54, CD9, CD81 and integrins [77]. Endocytosis by phagocytic cells occurs rapidly with most studies observing exosome internalization in as little as 30 minutes [30]. Exosomes are initially contained in early endosomes, which can then be processed to late endosomes approximately two hours following active up-take [77]. At this point, exosomes can be degraded and their cargo can be processed, such as peptides being presented to T-cells or signals from microRNAs [77].
Alternatively, exosomes can reside in recycling endosomes resulting in enhanced intercellular transport and release through transcytosis [53, 97]. In comparison, non-phagocytic cells display lower levels of exosome uptake mainly due to exosomes remaining bound to the cell surface [30]. Endocytosis appears to be dependent on actin, Annexin2, Annexin6 and dynamin2 but can occur with or without clathrin [58, 30]. Recipient cell internalization has been shown in various cell lines including: dendritic cells, macrophages, cancer cells and liver cells [77, 51, 70].

1.3.d Exosome markers

Exosomes have a unique lipid composition that can be used to distinguish them from apoptotic bodies and microparticles [15]. Exosome characterization is achieved through shape, size and by probing for common exosome markers [71]. Protein content can vary depending on the exosome’s cell-of-origin; however, there are some proteins more commonly found within exosomes which can be used for exosome identification [112]. These universal exosome markers may have essential roles in exosome formation [117] as they include proteins involved in the endocytic pathway (tetraspaninis – CD63 and CD81), cell structure (actin and tubulin), membrane proteins (Flotillin-1 and 2), antigen presentation peptides (MHC I and MHC II), cell adhesion proteins (integrins), stress regulators (Hsc70 and Hsp90), apoptosis related proteins (ALIX) and intracellular transport proteins (annexins) [104, 100]. Expression levels of universal markers vary between cell types, as well as between exosomes and their corresponding donor cells [117]. This variation decreases the reliability of some of these markers as loading controls i.e. actin [117]. Proteins rarely found within exosomes, including proteins that localize to the mitochondria and endoplasmic reticulum, i.e. SMAC and calnexin respectively, are used as negative exosome markers [33].
Unfortunately these proteins can sometimes be captured in exosomes during budding. Therefore neither the positive nor negative exosome markers are a perfect system.

1.3.e Exosome functions

Research in exosomes boomed in the late 90’s when it was determined that exosomes are released from a number of cell types and are implicated in other roles besides waste removal [52]. These functions include but are not limited to: antigen presentation, antiviral activity, cellular adhesion and cell signalling [70]. Many studies have shown the contribution of exosomes in the immune system. Exosomes produced from B cells express MHC II molecules and are able to participate in antigen presentation to stimulate T-cells [87]. Studies suggest that exosomes are able to activate T-cells both directly and indirectly with the aid of dendritic cells [15]. This may be dependent on the type of T-cells as well as the exosome’s ability to transfer MHC molecules to dendritic cell populations [105]. Exosomes aid in immune function through other means including transfer of antiviral molecules induced by IFN-α activation [58]. Second, exosomes aid in cellular adhesion. Exosomes function to enhance adhesion of cells to each other and culture dishes, implying that exosomes themselves are quite successful at cellular attachment [53]. Studies done by Clayton et al showed the ability of exosomes to interact with components of the extracellular matrix and other cells through integrin molecules expressed on their surface [20]. Lastly and most importantly, studies have shown that exosomes are able to transfer information in the form of mRNA, microRNA and proteins between cells resulting in phenotypic change in the recipient cell [108, 112]. For instance, normal cells use exosomes as messengers to prevent the growth of tumours by releasing growth-inhibitory signals in the form of microRNAs [51]. Of note, these signals do not prevent the growth of healthy cells, suggesting differences
Valadi et al found the RNA packaged in exosomes tended to have roles in cell development, protein synthesis and post-translational modifications [108].

Although exosomes have a number of advantageous functions for the host, they can be exploited to aid in tumour growth and the spread of pathogens [40, 86]. Within a tumour microenvironment, exosomes can be used to promote invasiveness and motility [86]. For example, studies have shown that miRNAs, i.e. miR-210 and miR-21, can be transferred through exosomes to enhance cancer metastasis, angiogenesis and apoptosis [49, 41]. In fact, cancer cells are thought to up regulate exosome release and/or secrete exosomes with higher protein concentrations than non-cancerous cells [49]. Similarly, viruses and intercellular pathogens have been shown to be contained within exosomes including: hepatitis C, HIV negative regulatory factors, Epstein-Barr miRNA and prion proteins [85, 97]. Not only does this aid in the pathogenicity and spread to adjacent cells, but this also functions to mask the pathogen from antibody-mediated neutralization [85].

1.3.f Exosome therapeutics

Exosomes are found in various body fluids, including urine and serum, where in the latter exosomes are estimated to have a concentration of three million/µL [112]. The presence of exosomes in body fluids suggesting they are able to circulate throughout the body whilst functioning in intercellular communication [15]. Studies of exosome delivery in vivo have shown a very short half-life in serum, approximately two minutes, and localization predominantly to the liver, with some detection in the lungs, kidneys and spleen [102]. Fortunately, studies have shown that exosomes can be genetically modified to alter their targeting for disease treatment [62]. Alvarez et al showed that neuronal-targeted exosomes were able to cross the blood brain barrier, be taken up by neurons in the brain and delivered
functional siRNA cargo [2]. Currently, exosome treatments are being tested in Phase 1 and 2 clinical trials for melanoma, non-small cell lung cancer and colorectal cancer [28, 112]. In these studies, exosomes are collected, purified, and the desired protein is attached directly to the exterior of the exosomes, which is referred to as direct loading [112]. The direct-loaded exosomes were then redelivered into the same individual as a vaccine to treat different types of cancers [112]. In this way, the immune system will not reject the exosomes; however this process must be carried out on an individual basis [112]. Other studies have shown that exosomes can also be loaded with cargo through electroporation [2]. Another avenue of investigation is looking at combining exosomes and gene therapy, as AAV caspids can associate with microvesicles and this interaction enhances viral infectivity in vitro [67]. Furthermore, exosomes have potential to be useful therapeutics since they appear well tolerated from both toxicological and immunological standpoints and they do not show decreased efficiency with repeated administration [2]. Lastly, since exosomes are not alive they can be easily stored and retain their biological activity [112].

Exocarta is an online database that has been created to assist exosome investigators in sharing data. To date, over 4,500 proteins, 1,600 mRNAs and 750 mircoRNA have been identified within exosomes isolated from different species and cell types [71]. Exocarta also describes different exosome purification methods, for instance differential centrifugation is used by 84% of studies, ultra-centrifugation is used by 30% of studies, and immunoaffinity-based isolation is used in only 9% of studies [71]. Of note most studies are now using a combination of purification techniques including the addition of filtration steps to enhance protocol stringency and homogeneity of the final sample [71]. Commercial fits including Exoquick and Exomir are also available as an alternate exosome collection method.
1.4 **Rationale**

SMA is caused by the deficiency of SMN, which results in α-motor neuron and skeletal muscle deterioration. Systemic addition of SMN could lead to phenotypic, lifelong correction of the defects caused by SMA. As such, two different methods, both involving an SMN expressing Ad vector, were investigated to enhance SMN levels *in vitro* and *in vivo*. First (1) we investigated whether a reduction in the Ad fiber protein, to reduce the overall size of the virus, could enhance gene delivery to muscle and motor neurons. Second (2) we investigated whether the liver could be used as a protein production factory to produce large amounts of a secreted SMN protein for circulation and uptake throughout the body. Surprisingly, our initial studies determined that SMN is naturally released from cells in exosomes which caused us to explore this process as a potential novel therapeutic.

1.5 **Hypothesis**

There are two major hypotheses, one for each approach:

1. Ads fiber protein can be modified to allow for altered infection tropism and decreased overall size of the virion resulting in enhanced dissemination throughout the body.

2. Following liver transduction of an SMN-expressing Ad vector, virally produced SMN can be secreted from cells, spread throughout the body, be taken up by other tissues and function in recipient cells.
1.6 **Objectives**

The specific aims designed to test these hypotheses are:

1. (i) Generate an Ad virus which infects the desired tissues, i.e. the spinal cord and skeletal muscle, (ii) determine the most effective delivery method and (iii) investigate the optimal viral dose to be used *in vivo*.

2. (i) Determine if SMN can be released from cells (ii) investigate how SMN release can be enhanced (iii) evaluate if released SMN is taken up by recipient cells and (iv) study this process *in vivo*. 
Chapter 2 – Materials and Methods

All solutions are described in detail in Appendix 1

2.1 **Cell culture.** All cell culture media and reagents were obtained from Invitrogen (Burlington, ON). Monolayers of human embryonic kidney 293 cells [36], 293N3S [35] and adenocarcinomic human alveolar basal epithelial A549 cells (American Type Culture Collection) were grown in complete minimum essential medium (MEM) (see Appendix 1). Rat cholinergic motor neuron MN1 cells [93] were graciously provided by from Dr. Jocelyn Cote (University of Ottawa) and were maintained in complete Dulbecco's modified Eagle's medium (DMEM). Undifferentiated mouse myoblast C2C12 cells [7] were grown in complete DMEM. Confluent plates were switched to differentiation medium for 4 days in order to induce myotubes differentiation.

2.2 **Cloning and Nucleofection.** A new cell line, A549::SMN, was created from a pCD2-SMN [24] plasmid digested with Xbal, BamH I and BgI II to allow for the insertion of EMCV/IRES and hygromycin resistance. This new plasmid was transfected into A549 cells using the Amaxa Cell Line Nucleofector Kit T (Lonza). Cells were pooled following transfection and positive cells were selected for using 150 µg/mL hygromycin (Invitrogen) in complete MEM.

2.3 **Generation and propagation of viruses.** A plasmid, pRP2014, containing an Ad5 genome excluding Ad5 E1 and E3 region was used as the backbone for all viruses in this study [84]. The viruses are replication defective and were generated using standard techniques [89]. A cytomegalovirus (CMV) immediate early enhancer/promoter-β-galactosidase expression cassette (pCA38) [1] was inserted in place of the E1-deletion, using RecA-mediated recombination [18], as detailed previously [114] to create the control virus Ad5LlacZ. Drs. Dmitry Shayakhmetov and Andre Lieber (University of Washington) kindly
provided a plasmid containing a modified fibre protein with the Ad9 shaft and Ad5 knob [98]. The modified fibre gene was subcloned into pRP2014 along with pCA38 and designated Ad5SlacZ. To introduce the poly-lysine motif into the H-I loop of the knob domain, a BglII/PstI fragment containing this region was first subcloned into pSP72 (Promega). This plasmid was PCR amplified and the linear product recircularized creating a molecule encoding a short fibre knob domain that has been changed from GDTT-PSAY to GDTT-AGKKKKKKKGA-PSAY. The resulting plasmid was recombined with pRP2014 and pCA38 and designated Ad5SpKlacZ (Figure 3.1).

Additional viruses were created from plasmids containing Flag-SMN, Flag-SMN-myc-his or Flag-SP-SMN [14]. Once again, plasmids were subcloned into pRP2014, with the transgene under regulation by the CMV immediate early enhancer/promoter, and designated Ad-SMN, Ad-SMN-myc-his or Ad-SP-SMN respectively (Figure 4.1). All viruses were created and purified by Dr. Robin Parks or Kathy Poulin.

2.4 **Particle counts.** An aliquot of virus was diluted in assay buffer, heated for 20 minutes at 65°C, and the absorbance determined as \(1\text{A}_{260} = 1.1 \times 10^{12}\) particles.

2.5 **In vitro infections.** Triplicate 35 mm dishes of A549, MN1, or undifferentiated or differentiated C2C12 cells were seeded at a density of 0.3 x 10^6 cells per 35 mm dish. The following day cells were infected at an MOI (multiplicity of infection) of 10 with Ad5LlacZ, Ad5SlacZ or Ad5SpKlacZ (or mock infected). All viruses were diluted in PBS to a final volume of 200 µL. Infections were done for 1 hour at 37°C with periodic rocking to redistribute virus on the monolayer, then 1 mL fresh media was added to the cells. Crude protein extracts were prepared from the infected cells 24 hours post infection (hpi) by lysing the cells with 175 µL of Lysis Solution (Applied Biosystems). The samples were centrifuged at 9400 xg for 2 minutes at room temperature (RT), the supernatant was then collected and
stored at -80°C. Infections with Ad-SMN and Ad-SP-SMN were done on confluent 35 mm or 150 mm dishes of A549 cells at MOI 5, 10, 25, 50 or 100. Twenty-four hpi, media was collected and crude protein extracts were harvested using 200 µL of 2x LD (Laemmli loading dye) per 35 mm dish. Samples were stored at -20°C until use.

2.6 **Trichloroacetic acid media precipitation.** Duplicate 35 mm dishes of confluent cells were washed with PBS prior to adding complete media. In the case of virally infected cells, washing took place immediately after the 1 hour infection period. After a 24 hour incubation, media was collected and centrifuged at 2,500 x g for 5 minutes. The supernatant was collected. Two hundred and fifty µL of 100% trichloroacetic acid (TCA) was added to 1 mL media and incubated on ice for 1 hour. The solution was centrifuged at 16,000 x g for 5 minutes. The supernatant was removed the pellet was washed with 200 µL 100% ethanol and centrifuged at 16,000 x g for 5 minutes. Again the supernatant was removed and the pellet resuspended in 100 µL 2x LD. Samples were stored at -20°C until use.

2.7 **In vivo injections.** Five different viruses were tested: Ad5Llacz, Ad5Slacz, Ad5SpKlacz, Ad-SMN and Ad-SMN-myc-his. Three viral concentrations were used 5×10^{11} VP/kg (low), 1×10^{12} VP/kg (middle) and 5×10^{12} VP/kg (high). Six to eight week old C57Bl/6J (Charles River) or CD1 mice were injected intravenously (IV - tail vein) or intraperitoneally (IP) with 100 µL virus (or mock infected) or TA (tibialis anterior) injected. For TA injections, mice were anesthesized with halothane, and injected with virus diluted in PBS or in 16 mg/mL Dextran Texas Red Fixable dye (Life Technologies) to a final volume of 25-30 µL for both the right and left TA muscle. One, two or three days post injection mice were euthanized with 100 µL euthanyl (CDMV Inc., Quebec City, QC) followed by decapitation (CDMV, Quebec City, QC) or sacrificed through cardiac puncture and chest
opening. All procedures were approved by the University of Ottawa Animal Care Facility and Animal Care Committee protocol review group.

2.8 **Tissue Homogenization.** Liver, TA muscle, and spinal cords were removed, immediately frozen in liquid nitrogen and stored at -80°C. Full livers were homogenized in 1 mL of PBS using a Power Gen 125 homogenizer (Fisher Scientific) at speed 5.5 for approximately 10 seconds or until no solid chunks were visible. Samples were incubated on ice, then sonicated using a Vibra Cell (Sonic Materials Inc.) twice for 15 seconds with a 10 second rest period between. Spinal cords were homogenized in 300 μL of PBS using a Power Gen 125 homogenizer at speed 4.5 for approximately 10 seconds or until no solid chunks were visible. Samples were incubated on ice then sonicated once for 15 seconds. Both liver and spinal cord samples were then centrifuged at 850 xg for 10 minutes and the supernatant collected. Sample supernatant was either stored at -20°C until use or if the samples were to be used for β-galactosidase (β-gal) determination further processed. TA muscles were homogenized using a liquid nitrogen chilled mortar and pestle. The ground muscle was then resuspended in 400 μL RIPA buffer. Both liver and TA samples from mice injected with a β-gal-expressing virus were further processed by heating in a 55°C water bath for 15 minutes, followed by centrifugation at 16,000 xg for 10 minutes. The supernatant was collected and stored at -20°C.

2.9 **Tissue Sectioning.** TA muscles, spinal cord, and diaphragm were removed and immediately incubated in 2% paraformaldehyde (PFA) fixative for 1 hour, followed by 3 washes in PBS and a final incubation in 30% sucrose for 48-72 hours. Tissues were equilibrated in 50:50 30% sucrose:OCT (Tissues Tek 4583) solution for 1-2 hours on a rocking platform. Samples were embedded in the same 50:50 mixture by flash freezing in
liquid nitrogen and stored at -80°C until sectioning. These tissues were later sectioned in transverse or longitudinal 12µm sections using a Leica CM 1850 and stored at -20°C.

2.10 β-galactosidase staining. Sectioned tissues were hydrated in PBS for 1-2 minutes and then fully submerged in X-gal stain for 24 hours at 37°C. Slides were washed in PBS for 1 minute and covered with a 1:1 PBS:30% glycerol solution and a glass cover slip. Quantification of the stained areas was performed using ImageJ (Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, Maryland, USA). A color intensity threshold was applied to determine the area of the muscle section showing X-gal staining, which is reported as the percentage of the total cross-sectional area of the muscle.

2.11 Exosomes collection. Confluent 150 mm plates of A549, A549::SMN or 293 cells were washed twice with PBS and then incubated in unmodified MEM for 24 hours at 37°C. Ad-SMN infected A549 cells, were infected at MOI 50 and washed with PBS immediately following infection to remove unattached virus. Exosomes were harvested using three different methods (i) ultracentrifugation, (ii) ultracentrifugation and filtering or (iii) Exoquick (System Biosciences). To harvest exosomes via ultracentrifugation, the media was collected and centrifuged at 2,000 xg for 20 minutes. This supernatant was transferred to new tubes and centrifuged at 10,000 xg for 30 minutes. The supernatant was transferred to new tubes and centrifuged at 100,000 xg for 1.5 hours. The supernatant was discarded, the pellet was resuspended in PBS and centrifuged at 100,000 xg for 1 hour. The pellet was then collected and resuspended in approximately 100 µL of PBS and stored at -80°C. To harvest exosomes by ultracentrifugation and filtration the 10,000 xg centrifugation step was replaced with a filtration step using a 0.2µm filter. This latter method was used for all exosome experiments unless stated otherwise. To harvest exosomes using the Exoquick reagent the System Biosciences protocol for Exoquick-media (Catalogue number: SYEXOTC2A1) was
followed and samples resuspended in deionized water. Exosome concentration was determined using a Bradford (Bio-Rad) assay with (addition of 10 µL RIPA to lyse the exosomes) or without exosome lysis. The size of exosome particles was determined through Nanoparticle Tracking Analysis using a Brunel Microscope Ltd Nanosight and NTA 2.3 Analytical Software. The Nanosight was set to a 60 second duration, 15-20 millisecond shutter time, automatic blur with threshold level varying between samples. For comparison, Dr. Dylan Burger (University of Ottawa) kindly supplied us with purified apoptotic bodies, microparticles, exosomes, vesicle free media and cell lysates, all resuspended in RIPA from human umbilical vein endothelial cells (HUVECs).

Serum exosomes were harvested following cardiac puncture, blood was allowed to clot for approximately 2 hours at RT. Blood was centrifuged at 1,000g for 10 minutes and serum was collected and stored at -80°C. Serum exosomes were harvested using Exoquick-serum (catalogue number: SYEXOQ5A1) as per the manufacturer’s instructions.

2.12 Analysis of exosome-mediated delivery of protein to cells. A549 cells were incubated with 5 ug exosomes for 4 hours. Following incubation, cells were wash with PBS and harvested for immunoblot using 2x LD.

2.13 Chemiluminescent β-galactosidase assay. Homogenized tissues, cells harvested in Lysis Solution (Applied Biosystems) and exosomes were assayed for β-gal activity using a commercial kit Galacto-star (Applied Biosystems) as per the manufacturer’s instructions. In all cases, 10 µL of sample was incubated for 1 hour in the reaction solution and analyzed for 1 second using a 20/20n luminometer (Turner BioSystems). Tissue data was normalized to the amount of protein in each sample, as determined by Bradford assay (BioRad).

2.14 Immunofluorescence analysis. Tissue slides were blocked in BSA (bovine serum albumin) Blocking Buffer for 1 hour. All incubations were preformed in a dark humidified
chamber. After blocking, 1/400 β-gal (Invitrogen) or 1/800 laminin (Invitrogen) primary antibody diluted in BSA Blocking Buffer was applied and stored at 4°C overnight. Slides were washed 3 times with PBS and incubated with 1/500 anti-rabbit-FITC (Invitrogen) or 1/500 anti-chicken-Alexafluor-488 (Invitrogen) secondary antibody for 1 hour. Slides were washed 3 times with PBS and covered with Dako fluorescent mounting medium (Dako) and a glass cover slip. Slides were stored at 4°C for a minimum of 24 hours before viewing. A549 and A549::SMN cells were grown for 24 hours on 18 mm disks (Fisher) contained in 35 mm dishes. Cells were washed twice with PBS and fixed for 10 minutes with 1 mL 4% PFA per 35 mm plate. The cells were washed twice with PBS then covered with BSA Blocking Buffer for 30 minutes. The BSA Blocking Buffer was removed and the cell covered disks were placed on glass slides. The cells were incubated with 1/500 Flag primary antibody diluted in BSA Blocking Buffer overnight at 4°C. The primary antibody was removed and the cells washed 3 times for 5 minutes with PBS. The secondary antibody, 1/5,000 anti-rabbit-FITC (Invitrogen), was then incubated with the cells for 1 hour at RT in the dark. The secondary antibody was removed and the cells were washed twice for 5 minutes with PBS. Cells were covered with Hoechst diluted in BSA Blocking Buffer, to a final concentration of 0.2 µg/mL, for 20 minutes at RT in the dark. The Hoechst (Life Technologies) was removed and the cells were washed 3 times for 5 minutes with PBS. Dako mounting solution was added and the cells were covered with a glass cover slips. Slides were stored at 4°C in the dark.

2.15 **Immunoblot analysis.** Western blot was used to determine the presence of various proteins in TCA precipitates, cells lysed in 2x LD, exosomes, serum, homogenized tissues and to examine the accuracy of Ad particle counts. Samples were diluted in 2x LD. Viruses were diluted to $10^9$ viral particles in PBS and 2x LD. All samples were boiled for 5 minutes
at 100°C and separated by electrophoresis on a 12 or 15% SDS-polyacrylamide gel. The separated proteins were transferred using a Trans-blot SD Semi-Dry transfer cell (Bio-Rad) for 1.5 hours to a polyvinylidene difluoride membrane (Immobilon-P, Millipore). The membrane was then incubated in Milk Blocking Solution for 1 hour prior to probing with various primary antibodies overnight at 4°C (Table 2.1). Binding of the primary antibody was detected using a goat anti-mouse 1/10,000 or goat anti-rabbit 1/5,000 secondary antibody conjugated to horseradish peroxidase (BioRad) for 1 hour at RT. Washing was done three times for 5 minutes with TBST between each incubation period. Proteins were visualized by chemiluminescence reaction (Thermo Scientific ECL western blotting substrate) and autoradiography.

2.16 **Statistical analysis.** Statistical significance of the data was determined using ANOVA and Sigma Stat software. Groups which contained a significant difference were further processed by Dunn’s or Tukey tests as recommended by the Sigma Stat program. All error bars represent standard deviation and the p-value was set to 0.05.
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Species</th>
<th>Dilution</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Ad</td>
<td>Rabbit</td>
<td>1/10,000</td>
<td>Abcam</td>
</tr>
<tr>
<td>Pan-actin</td>
<td>Rabbit</td>
<td>1/10,000</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Alix</td>
<td>Rabbit</td>
<td>1/1000</td>
<td>Sigma</td>
</tr>
<tr>
<td>β-gal</td>
<td>Rabbit</td>
<td>1/1,000</td>
<td>Life Technologies</td>
</tr>
<tr>
<td>Calnexin</td>
<td>Rabbit</td>
<td>1/1,000</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Flag</td>
<td>Mouse</td>
<td>1/10,000 - cells</td>
<td>Sigma</td>
</tr>
<tr>
<td>Flotillin-2</td>
<td>Rabbit</td>
<td>1/1,000</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Mouse</td>
<td>1/20,000</td>
<td>Abcam</td>
</tr>
<tr>
<td>His</td>
<td>Mouse</td>
<td>1/1,000</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Myc</td>
<td>Mouse</td>
<td>1/1,000</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>SMAC</td>
<td>Rabbit</td>
<td>1/1,000</td>
<td>ProSci</td>
</tr>
<tr>
<td>SMN</td>
<td>Mouse</td>
<td>1/10,000 - cells</td>
<td>BD Transduction</td>
</tr>
<tr>
<td>SMN</td>
<td>Rabbit</td>
<td>1/1,000</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Tubulin</td>
<td>Mouse</td>
<td>1/10,000</td>
<td>Oncogene</td>
</tr>
<tr>
<td>Tubulin</td>
<td>Rabbit</td>
<td>1/10,000</td>
<td>Abcam</td>
</tr>
</tbody>
</table>
Chapter 3 – Reduced virion size does not enhance viral distribution \textit{in vivo}

3.1 Introduction

The goal of this project was to enhance virus delivery to muscle and motor neurons, the damaged tissues in SMA, through reducing the overall diameter of the virus by 30\%. To achieve this reduction in size the Ad5’s fiber protein was modified. Fiber is one of the three major capsid proteins and is composed of a tail, shaft and knob domains [72]. Fiber is projected from the capsid surface and therefore increases the diameter of the total virion [72]. The primary function of fiber is to initiate viral binding with the host cell through interactions with cellular receptors, usually CAR [68]. Fiber proteins from different Ad serotypes can vary in tissue tropism and fiber binding can be further altered through genetic or covalent modifications [84].

A series of fiber modified Ad constructs were created and tested by previous lab members [34]. Ad5 was used as a control to determine the efficiency of infection of the modified viruses. Preliminary results suggested that two of these viruses have potentially altered biodistribution. Both modified viruses contain an Ad9 shaft with an Ad5 knob. This modification decreases the overall size of the virion by 50 nm, possibly improving systemic distribution. Constructs containing the Ad9 shaft are referred to as short (S), whereas control Ad5 constructs are long, (L), Figure 3.1. The second modification is the addition of 7 lysine residues to the H-I loop in the fiber knob of a virus containing the shortened Ad9 shaft designated Ad5SpKlacZ. These additional poly-lysine residues increase specificity to cellular heparan sulphate proteoglycans instead of CAR [11]. Since not all cell types have high CAR expression, i.e. mature muscle, the poly-lysine modification allows for an increase in the number of cellular targets the virus can infect. As well, poly-lysine residues increase the overall charge of the virion, possibly improving interactions with the negatively charged
A

Ad5L

Ad5S

95nm

37nm

169nm

119nm

B

CMV β-gal pA

Fibre

ΔE1

ΔE3

<table>
<thead>
<tr>
<th>Shaft</th>
<th>Knob</th>
<th>Modification</th>
<th>Shaft Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad5L lacZ</td>
<td>Ad5</td>
<td>---</td>
<td>37nm</td>
</tr>
<tr>
<td>Ad5S lacZ</td>
<td>Ad9</td>
<td>Ad5</td>
<td>11nm</td>
</tr>
<tr>
<td>Ad5Spk lacZ</td>
<td>Ad9</td>
<td>Ad5 pk</td>
<td>11nm</td>
</tr>
</tbody>
</table>
Figure 3.1 *Viral constructs.*
Panel A: General capsid structure of the viruses used in this study.
Panel B: General genetic structure of the viruses used in this study. All viruses are deleted of E1 and E3, and contain the same *E.coli* lacZ gene under regulation by the human CMV immediate early enhancer/promoter and bovine growth hormone polyadenylation sequence (pA). Ad5LlacZ encodes the native Ad5 fibre protein. Ad5SlacZ encodes a chimeric fibre protein with an Ad9 shaft and Ad5 knob. Ad5SpKlacZ is similar in structure to Ad5SlacZ, but contains a poly-lysine motif in the H-I loop of the fiber knob domain.
Throughout this chapter, I investigated: (i) which Ad construct best infects the desired tissues, i.e. the spinal cord and skeletal muscle, (ii) the most effective delivery method, and (iii) optimal viral dose. Initial experiments were done using a β-gal reporter gene for tracking. As all construct have the same promoter region, β-gal expression was used as a marker for infection efficiency. These studies will serve to establish the best vector and conditions for Ad-mediated gene therapy for SMA in the future. A manuscript for this project has been published in Virology (Appendix 2).

3.2 Results

3.2.a Ad vectors are able to infect both motor neurons and muscle cells in vitro

In vitro infections were preformed to ensure all Ad constructs were able to efficiently infected motor neurons and muscle cells. Viral titers were determined by particle count and their accuracy confirmed through immunoblot analysis of the major caspid protein hexon, Figure 3.2A. Immunoblot was further used to confirm differences in fiber size for the various viral constructs. As expected, the modified constructs containing an Ad9 shaft had significantly reduced fiber size compared to the control Ad5 virus, shown by the 15 kDa difference in Figure 3.2B. Next MN1, A549, undifferentiated and differentiated C2C12 cells were infected at a MOI of 10 with the various viruses and the infected cells harvested in lysis buffer (Applied Biosystems) at 24 hpi. Viral transgene expression was determined through a chemiluminescence β-gal assay. Our data showed all three viruses infected MN1 cells relatively consistently with a 10-fold increase in luminescence compared to the PBS control, Figure 3.3B. MN1 cell infection efficiency was lower than A549 cells, which expressed a 100-1000 fold increase in β-gal activity in the viral constructs relative to PBS, Figure 3.3A.
Figure 3.2 *Ad5LacZ, Ad5SlacZ and Ad5SpKlacZ differ in fiber size.*

Panel A: Viral titers determined through particle count, were confirmed through separating $10^9$ viral particles by SDS-PAGE, and probing the resulting membrane for hexon protein. Data represents n=3

Panel B: $10^9$ virus particles were separated by SDS-PAGE and probed for fiber. Data represents n=2
**Figure 3.3** Infection of Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in established cell lines derived from different tissues. A549 (A), MN1 (B), and undifferentiated (C) or differentiated C2C12 (D) cells were infected at an MOI of 10 with Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or mock infected with PBS. The quantity of β-gal expressed 24 hpi was assessed by chemiluminescent assay. Data represents n=3, with average and standard deviation shown. *= p<0.05.
Undifferentiated and differentiated C2C12 cells have nearly identical infection profiles, again with 100-1000 fold increase in luminescence compared to the PBS control, Figure 3.3C-D. Both Ad5LlacZ and Ad5SlacZ showed similar infection levels in C2C12 and A549 cells, while Ad5SpKlacZ had a 10-fold lower infection efficiency in C2C12 cells. All viruses showed enhanced infection efficiency in C2C12 cells compared to MN1 cells, with Ad5LlacZ demonstrating the most dramatic difference with a 10-fold increase. Overall, the results suggest that all the constructs were able to infect motor neuron and mature muscle cells in vitro, with Ad5LlacZ having a slightly higher degree of efficiency than the modified constructs.

3.2.b  Ad vectors predominately localize to the liver and the site of injection

To examine viral spread in vivo, all 3 objectives - different constructs, injection methods and concentrations - were explored in parallel. As the constructs showed similar infection efficiency in vitro, experiments were continued with all three viruses. IP, IV and TA injections were investigated, as well as three viral concentrations $5 \times 10^{11}$ VP/kg (low), $1 \times 10^{12}$ VP/kg (middle) and $5 \times 10^{12}$ VP/kg (high) however, only the high concentration was tested for TA injections. C57Bl/6J mice were chosen as they represent the background of the SMN<sup>2Bl</sup>-SMA mouse model. Injections were preformed with mice between six and eight weeks of age. After a 24 hour exposure period, mice were euthanized and tissues harvested. Tissue infection was detected using a chemiluminescent assay and β-gal staining. Livers and TA muscles were homogenized for analysis via chemiluminescence assay, Figure 3.4. After systemic delivery Ad predominately accumulates in the liver, therefore high liver infection was expected. This was observed for both TA (Figure 3.4B) and IV injections (Figure 3.4F), where IV injections demonstrated increased transgene expression in a dose dependent
Figure 3.4 Analysis of transgene expression from Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in TA muscle and liver. Six to eight week old C57Bl/6J mice (n=2-3 per treatment) were injected with a low (5x10^{11} VP/kg), middle (1x10^{12} VP/kg) or high (5x10^{12} VP/kg) dose of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or PBS by either TA (Panel A and B), IP (Panel C and D) or IV (Panel E and F) injections. Twenty-four hours post injection, the TA muscle (n=2-5) or liver (n=2-3) were removed, processed, and assayed for β-gal activity (normalized to µg of protein in the sample). Average and standard deviation are shown. *= p<0.05.
manner. Surprisingly, high liver infection was not observed following IP injections, where expression for Ad5SlacZ and Ad5SpKlacZ in the liver remained similar to PBS, Figure 3.4D. This observation suggested that the viruses were mainly located elsewhere throughout the body. In all three injection methods, Ad5LlacZ resulted in the highest, while Ad5SpKlacZ had the lowest levels of liver infection; however, this was not statistically significant. We also determined Ad infection was prominent at the site of injection, as observed in the TA muscle following TA injections. In this case, all three viruses have roughly a equivalent 100-fold increased β-gal expression compared to PBS (Figure 3.4A). Both IV and IP injections showed minimal or no transgene expression in the TA muscle, suggesting neither fiber modification enhanced viral spread to distal muscle tissue (Figure 3.4C and 3.4E). Of note, there is a single outlier within the IV injections where at high concentration Ad5LlacZ shows significant TA infection. The reason for this outlier is unknown and was not reproducible. Taken together, these results indicate exclusive infection of the liver and site of injection with no enhancement in uptake by muscle tissue with these fiber modifications.

The overall trend of viral infection remaining localized at the site of injection was supported through β-gal staining of tissue sections. Tissues analyzed by staining were submerged in 2% PFA fixative for 1 hour, sectioned in transverse slices of 12 µm, and stained for approximately 24 hours at 37°C in X-gal stain. β-gal expression was detected in the TA muscle following TA injections, Figure 3.5A, where enhanced infection is observed in Ad5LlacZ and Ad5SpKlacZ relative to Ad5SlacZ. Transgene expression was not detectable in the TA muscle following IP or IV injections, Figure 3.5B-C. The diaphragm was tested as an additional muscle tissue as it is in close proximity to the injection site for IP injections. Following IP injections, the lower edge of the diaphragm showed positive viral
<table>
<thead>
<tr>
<th></th>
<th>TA injection</th>
<th></th>
<th>IP injection</th>
<th></th>
<th>IV injection</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Top</td>
<td>Middle</td>
<td>End</td>
<td>Top</td>
<td>Middle</td>
<td>End</td>
</tr>
<tr>
<td>TA muscle</td>
<td>PBS</td>
<td>Ad5LlacZ</td>
<td>Ad5SlacZ</td>
<td>Ad5SpklacZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal Cord</td>
<td>PBS</td>
<td>Ad5LlacZ</td>
<td>Ad5SlacZ</td>
<td>Ad5SpklacZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diaphragm</td>
<td>PBS</td>
<td>Ad5LlacZ</td>
<td>Ad5SlacZ</td>
<td>Ad5SpklacZ</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 3.5 Histological analysis of β-gal expression in the TA muscle, spinal cord and diaphragm of treated animals. Six to eight weeks old C57Bl/6J mice were treated with 5x10^{12} VP/kg of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or PBS by either TA, IP or IV injections. The TA muscle (Panel A - C), spinal cord (Panel D - F) and diaphragm (Panel G and H) were removed 24 hours post-treatment, fixed, sectioned, and stained for β-gal activity. Sections were viewed using an AxioCam Axiophot2 light microscope at 10X magnification. Data represents n=2 biological replicates.
infection with Ad5LlacZ, however the virus appeared unable to penetrate through the tissue, Figure 3.5G. There was no significant viral infection with either of the modified constructs or following IV injections. Lastly, following transverse sectioning, infection in the spinal cord was analysed for all injection methods. Unfortunately, β-gal staining was undetectable in all cases, suggesting the viral constructs were unable to reach the motor neurons or unable to spread within the spinal cord. Thus, the site of injection played a key role in determining which tissues were accessible for infection. Overall, the data indicated that even with a reduced diameter the viral constructs could not spread to distal muscle tissue or the spinal cord regardless of injection method or viral dose.

3.2.c Increased exposure periods did not result in enhanced infection in muscle tissue or retrograde transport to motor neurons

A study performed by Nakajima et al showed adenovirus is able to undergo retrograde transport and reach the CNS from various muscle groups in rats [79]. Retrograde transport is the movement up a neuron from a nerve ending to the CNS. Ad's ability to undergo retrograde transport suggests Ad vectors may be useful in treating neuron diseases. We wished to further investigate if we could establish a method to achieve efficient retrograde transport into the spinal cord following TA injections. Literature suggests that an increased exposure period could allow for enhanced retrograde transport [46]. As such, TA injections were repeated with tissues harvested 48 or 72 hours after injection. It is possible that increased exposure periods may alter viral infection in other tissues and, as such, liver and TA muscles were again harvested and analyzed via chemiluminescence assay. Liver samples showed a slight decrease in β-gal expression over time, Figure 3.6B, possibly due to the innate immune responses directed toward the vector. The same overall trend was
Figure 3.6 Analysis of Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in TA muscle and liver with extended exposure periods. Six to eight week old C57Bl/6J mice were injected in the TA muscle with 5x10^{12} VP/kg of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or PBS. Mice were sacrificed 1, 2 or 3 days post injection and TA muscles (Panel A; n=3) and liver (Panel B; n=2) were collected. Samples were processed and analyzed for β-gal activity by chemiluminescence assay. Average and standard deviation the mean shown. *= p<0.05.
observed for all viruses, with Ad5LlacZ having the greatest transgene expression and Ad5SpKlacZ having the lowest. In the TA muscle, all three viruses showed equivalent β-gal expression with very little variation over the three day time period, Figure 3.6A. To confirm these results, TA muscles were harvested and analyzed by sectioning and β-gal staining. Figure 3.7 showed whole cross sections of the TA muscle from the top, middle, and end of the tissue. When viewing the muscle as a whole, there appeared to be no difference in viral infection between the three viruses or over the three day incubation period. The area of transgene expression was quantified using ImageJ, Table 3.1; however, the magnitude of staining varied significantly between mice. The overall trend showed increased β-gal staining at the top of the tissue, nearest to the point of injection, relative to the bottom of the tissue. Averaging the nine values for each viral construct suggested Ad5LlacZ and Ad5S1acZ had nearly identical infection efficiency, while Ad5SpKlacZ showed a marginal improvement compared to the other constructs. Lastly, we analysed the area of transduction in the tissue sections through indirect immunofluorescence. Primary β-gal and laminin antibodies were incubated overnight for viral detection and cellular identification, respectively. Positive transgene expression was again detected as seen in Figure 3.8. These outcomes imply all constructs were able to infect both the liver and the TA muscle at all three exposure periods. However, our results showed no improvement in viral spread throughout the muscle or degree of infection with longer incubations.

To study Ad retrograde transport into the CNS not only were exposure times extended but sectioning was done in a longitudinal orientation and injections were done in the presence of Dextran Texas Red Fixable dye. It is known that the TA muscle tracks through the sciatic nerve to the L4-L6 regions of the spinal cord [46]. However, it is very difficult to locate and isolate these specific lumbar regions via transverse sectioning. As
<table>
<thead>
<tr>
<th></th>
<th>Top</th>
<th>Middle</th>
<th>Bottom</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>Ad5LlacZ</td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>Ad5SlacZ</td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
<td><img src="image9.png" alt="Image" /></td>
</tr>
<tr>
<td>Ad5SpKlacZ</td>
<td><img src="image10.png" alt="Image" /></td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
</tr>
</tbody>
</table>

A, B, C
Figure 3.7 Histological analysis of β-gal expression in the TA muscle after extended exposure periods. Six to eight week old C57Bl/6J mice were treated with $5 \times 10^{12}$ VP/kg of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or PBS by direct TA injection. The TA muscle was removed at 24 (Panel A), 48 (Panel B) or 72 (Panel C) hours post injection. Tissues were fixed, sectioned and stained for β-gal activity. Whole sections were viewed using a Leica M80 microscope. Data represents n=2 biological replicates.
Table 3.1 Area$^a$ of TA muscle expressing β-gal following TA injection.

<table>
<thead>
<tr>
<th>Time</th>
<th>Ad5LlacZ</th>
<th></th>
<th>Ad5SlacZ</th>
<th></th>
<th>Ad5SpKlacZ</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Top</td>
<td>Middle</td>
<td>Bottom</td>
<td>Top</td>
<td>Middle</td>
<td>Bottom</td>
</tr>
<tr>
<td>24h</td>
<td>25.1 ± 6.5</td>
<td>25.5 ± 4.2</td>
<td>35.9 ± 23.5</td>
<td>18.4 ± 10.7</td>
<td>20.4 ± 0.8</td>
<td>14.1 ± 5.1</td>
</tr>
<tr>
<td>48h</td>
<td>27.0 ± 13.4</td>
<td>25.0 ± 14.6</td>
<td>22.1 ± 11.8</td>
<td>42.1 ± 1.2</td>
<td>43.1 ± 3.6</td>
<td>21.9 ± 11.7</td>
</tr>
<tr>
<td>72h</td>
<td>20.0 ± 16.9</td>
<td>17.3 ± 10.6</td>
<td>13.3 ± 9.1</td>
<td>26.1 ± 5.1</td>
<td>21.8 ± 18.2</td>
<td>9.7 ± 8.6</td>
</tr>
</tbody>
</table>

$^a$ Images from stained sections were analyzed using Image J. A color intensity threshold was applied to determine the area of the muscle section showing X-gal staining, which is reported as the percentage of the total cross-sectional area of the muscle.
Figure 3.8 Immunofluorescence of TA muscles by α-β-gal and α-laminin. Six to eight weeks old C57Bl/6J mice were treated with 5x10^{12} VP/kg of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or PBS by direct TA injection and the TA muscle was removed at 24 (Panel A), 48 (Panel B) or 72 (Panel C) hours post injection. Tissues were fixed, sectioned and analysed by immunofluorescence using antibodies to β-gal and laminin. Data represents n=2.
such, longitudinal sectioning was done, since it allows for a greater region of the spinal cord to be analysed and improves the probability of locating the motor neurons which innervate the TA muscle. Viral constructs were diluted in Dextran Texas Red Fixable dye to allow visualization of the motor neurons which innervate with the TA muscle. Dextran is a hydrophilic polysaccharide efficient at retrograde transport and therefore commonly employed for fluorescent neuronal tracking [59]. TA injections were done using 16 mg/mL Dextran Texas Red Fixable dye along with 5x10^{12} VP/kg of virus. Following a 48 hour incubation period, mice were euthanized and spinal cords collected. The lumbar region of the spinal cord was sectioned longitudinally until motor neurons were detected by the immunofluorescent Dextran dye, Figure 3.9A. Sections immediately following those positive for motor neurons were then stained for approximately 24 hours with X-gal stain. Panel B of Figure 3.9 showed that virus is detectable in the motor neurons and therefore Ad does undergo retrograde transport. Our results were quite variable between mice, but Ad5SpKlacZ was observed to have the least success at retrograde transport. Overall, we did observe β-gal staining in the motor neurons, it was relatively inefficient and none of the modified viruses showed a significant enhancement in retrograde transport or motor neuron transduction.
Figure 3.9 Immunofluorescence analysis of motor neurons and histological analysis of β-gal expression. Six to eight week old C57Bl/6J mice were treated with 16 mg/mL Dextran Texas Red Fixable dye in 5x10^{15} VP/kg of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ or PBS by TA injection. Spinal cords were removed 48 hours post injection. Tissues were fixed and 12µm longitudinal sections were collected until motor neurons were detected by the immunofluorescent Dextran dye (Panel A). The next serial section was then stained for β-gal activity and viewed using a Leica M80 microscope (Panel B). Data represents n=2 biological replicates.
3.3 **Discussion**

3.3.a **Overview**

SMA is an autosomal recessive disorder with very early onset in children. The disease is characterized by the progressive deterioration of muscle tissue, leading to impaired mobility and breathing, often resulting in death [37]. SMA occurs due to low levels of the SMN protein generally resulting from a genetic mutation in the *SMN1* gene [56]. Several different treatment avenues are currently under investigation to increase the amount of SMN in the damaged tissues, specifically α-motor neurons and skeletal muscle. The goal in this chapter was to alter Ad vector distribution throughout the body and enhance infection in the damaged tissues. This improved Ad vector could then be used in the treatment of SMA. The Ad capsid protein, fiber, was modified with the hope of improving biodistribution and altering infection tropism. Unfortunately it was found that none of the modified constructs had improved infection relative to the control Ad5. In the majority of cases Ad constructs localized to the liver or remained at the site of injection.

3.3.b **Ad localizes predominantly to the liver**

Ad has been extensively studied over the past 60 years and its localization to the liver is well characterized [47]. This chapter investigated if modifications to the Ad fibre would show increased systemic spread by monitoring Ad accumulation within the liver. Analysis of the three different injection methods following a 24 hour incubation period, Figure 3.4, showed Ad5LlacZ gave the highest levels of liver infection. This result suggested that the modified constructs were infecting elsewhere throughout the body or being degraded and lost. Between the two modified constructs, Ad5SpKlacZ consistently showed the lowest levels of liver infection, implying the addition of poly-lysine to enhance viral interactions.
with cellular heparan sulphate proteoglycans does increase the number of cellular targets. IV injections demonstrated the highest levels of liver infection and did so in a dose dependent manner for all constructs. Surprisingly, IP injections demonstrated very low liver transgene expression. In the case of low viral concentration (5x10^{11} VP/Kg), β-gal expression levels were equivalent to the PBS control, implying the virus is being trapped elsewhere, most likely within the intraperitoneal space. Livers were analysed following TA injections from three different exposure periods, Figure 3.6B; however the same trend was observed, Ad5LlacZ and Ad5SpKlacZ had the highest and lowest infection levels, respectively. Although a decrease in β-gal expression was observed with increased exposure periods in the liver, there was no dramatic change in expression levels, suggesting minimal immune-mediated loss of the vector. Overall, these results suggest that the liver remains the primary site of infection for both TA and IV injections, and that the viral constructs are unable to reach the liver following IP injections. Furthermore, the three viral constructs did not have equivalent infection efficiencies, with Ad5LlacZ having the greatest and the modified constructs, in particular Ad5SpKlacZ, yielding slightly lower infection rates.

3.3.c Muscle infection is not enhanced through fiber modifications

As SMA affects the NMJ, it is currently debated whether SMA is a muscle disease or a neuron disease. Although it is ideal to have systemic SMN replacement, the replacement of SMN in α-motor neurons and skeletal muscle is vital. The addition of 7 lysine residues to the Ad5SpKlacZ construct was designed to increase muscle infection by enhancing specificity to cellular heparan sulphate proteoglycans, which has been shown previously by Bramson et al. [11]. Unfortunately, while Ad5SpKlacZ demonstrated the lowest rate of liver infection, this does not appear to be a result of enhanced muscle infection. In vitro experiments involving
C2C12 cells (Figure 3.3) showed no difference in viral infection between Ad5SpKlacZ and Ad5SlacZ, which lacks the poly-lysine motif. In fact, decreased infection efficiency was observed for Ad5SpKlacZ compared to the unmodified fiber, Ad5LlacZ. In vivo experiments were mainly analyzed using the TA muscle, where infection was detected following only TA injections (Figure 3.4 and Figure 3.5). Again, there was no significant difference between viral constructs suggesting the poly-lysine residue did not enhance muscle infection. The lack of viral infection in the TA muscle following IV and IP injections (Figure 3.4 and Figure 3.5) suggests that even at a reduced size the viral constructs are unable to spread systemically and rarely reach distal tissues. Likewise, lack of viral spread was observed in the diaphragm. Positive diaphragm staining was only observed following IP injections where the diaphragm is in close proximity to the site of injection. Transgene expression was observed with Ad5LlacZ in the bottom of the tissue indicating again the virus is unable to spread through muscle tissue. Surprisingly, infection was not detectable for the two modified viruses which had the lowest liver infection rate following IP injections and are smallest in size. The reason for this is unknown however, it is hypothesized that these viruses remain near the site of injection, infecting the membranes in the peritoneum.

It was thought that increased exposure periods may result in reduced β-gal activity due to activation of the murine immune system against the viral vector resulting in death of the transduced cells. However, this was not the case. Following TA injection, β-gal expression in the TA muscle remained constant over the 72 hour incubation period for all three viral constructs (Figure 3.6A and 3.7), implying Ad vectors are not cleared from muscle tissue for at least 72 hours. Rapid removal of Ad vectors is one of the major concerns in gene therapy however current studies suggest that helper dependent Ad is able to persist for years in vivo [12]. Overall, increased specificity to cellular heparan sulphate
proteoglycans did not enhance muscle infection relative to normal Ad5 fiber, nor did decreasing the virion size through changing the length of the fiber shaft. The lack of skeletal muscle infection following both IV and IP injections suggests that systemic spread did not occur and further modifications maybe be required to achieve efficient delivery to distant tissues using Ad vectors.

3.3.d **Spinal cord infection is detectable in the α-motor neurons**

For the proper treatment of SMA it is essential that the SMN protein be delivered to α-motor neurons. Previous studies have shown that Ad can undergo retrograde transport [79] and transport may be improved with increased exposure periods [46]. The TA muscle, representing the site of injection, tracks through the sciatic nerve to the L4-L6 regions of the spinal cord [46]. In cell culture, our studies showed that all constructs were able to infect MN1 cells (Figure 3.3B). However, in initial in vivo experiments, viral infection was not detectable within the spinal cord. This was attributed to the use of transverse sections which may not have contained α-motor neurons from the L4-L6 region. However, following TA injections at high viral concentration combined with Dextran dye, specific detection of motor neurons was possible and viral infection within the spinal cord was observed, Figure 3.9B. Dextran is a hydrophilic polysaccharide with low toxicity, commonly employed for neuron tracking due to its efficiency at anterograde and retrograde transport [59]. β-gal staining of sections positively identified with α-motor neurons confirmed positive viral infection at sites corresponding to the α-motor neurons. An accurate comparison between constructs was not possible due to large variability between samples and low sample size however potential trends were observed. Ad5SpKLacZ consistently had the weakest infection of α-motor neurons while Ad5SlacZ demonstrated minimal improved transgene expression over
Ad5LlacZ. It was thought that decreasing the overall size of the virion by changing the Ad5 shaft to the smaller Ad9 shaft could enhance retrograde transport and this was observed for Ad5SlacZ which showed slightly enhanced motor neuron staining. Ad5SpKlacZ did not result in enhance retrograde transport suggesting the reduced diameter may be beneficial only in the absence of poly-lysine residues. In all cases the viruses were able to reach the spinal cord and infect the motor neurons however viruses were unable to escape the motor neurons.

3.4 Conclusions

All constructs demonstrated positive infection *in vitro* with a variety of cell types, as well as, *in vivo* in the liver, TA muscle and motor neurons. No significant differences were observed between injection methods, as the viruses specifically infected the site of injection or the liver. Importantly, in terms of SMA, none of the viral constructs were sufficient for body-wide transduction. Overall despite reducing the vector size by changing the fiber shaft and increasing the number of cellular targets through the addition of poly-lysine residues the constructs were unable to specifically or effectively infect the desired tissues. These studies suggest that additional modifications to the Ad vector system are required to enhance its utility for treatment of SMA.
Chapter 4 - Exosome transport of SMN

4.1 Introduction

The goal of this project was to utilize the natural accumulation of virus in the liver as a protein production factory and investigate how this newly synthesised SMN protein can spread body-wide. Such an approach has been explored for diseases involving secreted proteins, as such as factor IX for the treatment of hemophilia [113]. It was determined in the previous chapter that IV injections result in significant dose dependent delivery to the liver. It is hypothesized that following infection significant amounts of viral encoded SMN will be transcribed. The challenge in treating SMA is to find a mechanism for this newly synthesized SMN to be released from hepatocytes, spread throughout the body and be taken up by recipient cells.

In order to address the issue of protein release a previous student in the lab created vectors encoding modifications to the SMN gene, Figure 4.1A [14]. These additions included an N-terminal secretory peptide (SP) to enhance release of the SMN protein from hepatic cells, as well as various tags. To verify the release of the SMN protein from cells, A549 cells were infected with Ad-SMN and Ad-SP-SMN at an MOI of 25, 100 or mock infected. Cells were harvested at 24 hpi using 2x LD, and cellular SMN and tubulin were detected using immunoblot. The 24 hour old media was also collected and, following TCA protein precipitation [45], the secreted proteins were analyzed by immunoblot. Figure 4.1B showed that SMN was present in both cells (bottom panel) and media (top panel) following infection from the two different viral constructs. It was determined that although Ad-SP-SMN contained a secretory peptide and Ad-SMN does not, significant amounts of SMN were observed in the media from Ad-SMN infected cells. This suggests that native SMN is released from A549 cells, and modifications to the SMN gene to enhance secretion of the
Figure 4.1 Analysis of SMN levels in cells and media for cell treated with Ad-SP-SMN or Ad-SMN.

Panel A: General structure of the viruses used in this study. All viruses are deleted of E1 and E3, and express Flag-SMN under regulation by the human CMV immediate early enhancer/promoter. Ad-SMN-myc-his encodes additional myc and his tags while Ad-SP-SMN encodes all three tags and a SP.

Panel B: A549 cells were infected at an MOI of 25 or 100 with Ad-SP-SMN and Ad-SMN (or mock infected), 24 hpi SMN expression was detected by immunoblot for both the cell lysates (bottom) and media following TCA precipitation (top). Equivalent volumes of cell lysate and TCA precipitate were applied to the gel. Data represents n=3.
protein may be unnecessary. This is further confirmed by the presences of SMN in the media of the mock infected cells observed in Lane 1 of Figure 4.1B. Additional experiments were performed to establish that SMN is secreted from cells and is not a consequence of the FBS in complete MEM. Media following a 24 hour incubation on A549 cells was compared to media not used for culturing, Figure 4.2A. After TCA precipitation, it was observed that media incubated on cells had enhanced SMN signal relative to media never exposed to cells. This corroborates our previous observation of natural SMN release however, it is unknown how SMN is being released. SMN is also released into the media from various other cell lines, Figure 4.2B. These cell lines are a mixture of both human and mouse cells as well as normal and cancerous cells together representing a variety of tissue types. Again SMN was detected in the media following TCA precipitation suggesting protein release. This novel knowledge may be useful in the development of an SMA therapeutic, therefore in this chapter I investigated: (i) how SMN is released (ii) how SMN release can be enhanced (iii) if secreted SMN is taken up by recipient cells and (iv) analysed this process in vivo.

4.2 Results

4.2.a SMN is present in exosomes

We first investigated how SMN is released into the media. Cells produce a variety of microvesicles which, depending on their size, are capable of carrying large numbers of proteins. Exosomes, the smallest of the microvesicles can carry up to 100 proteins and 10,000 nucleotides [70]. The exosome field is currently very active due to their new found role in cellular communication and immune function [52]. Studies have found that hepatocytes, like most cells, are able to produce and release exosomes [85]. Therefore, we investigated if SMN, a cytosolic protein, may be packaged into exosomes during MVB
**Figure 4.2** Native SMN is detectable in media following TCA precipitation.

Panel A: Media following a 24 hour incubation with A549 cells or media without incubation was subjected to TCA precipitation, separated by SDS-PAGE, and the resulting immunoblot probed for SMN. Equivalent volumes of TCA precipitate were applied to the gel. Data represents n=3.

Panel B: SMN expression after TCA precipitation of media following a 24 hour incubation on A549, C2C12, HeLa, Mef or 293 cells. Equivalent volumes of TCA precipitate were applied to the gel however cells were not plated at equal confluences. Data represents n=3.
internal budding. SMN’s natural expression in exosomes could potentially simplify the process of delivering this protein to recipient cells.

Exosome isolation was preformed using an exosome collection protocol involving a series of ultra centrifugation steps. The final sample representing exosomes was analyzed via Nanosight, Figure 4.3A. These particles were found to have a mean size of 260 nm. As exosomes are between 30-100 nm in diameter, our analysis indicates possible microparticle contamination. The exosome collection protocol was modified by exchanging the 10,000 xg centrifugation step with filtration through a 0.2 µm filter. This approach successfully reduced the mean particle size to 160 nm, Figure 4.3B. Although this does suggest a decreased amount of microparticles in the exosome sample, the preparation likely still contained a mix of exosomes and microparticles. The harvested exosomes were then analyzed by immunoblot using exosome positive, ALIX and Flotillin-2, and exosome negative, Calnexin and SMAC, markers. Figure 4.3C showed that the positive marker ALIX is detectable in both 293 and A549 harvested exosomes. In Figure 4.3D, A549 exosomes were compared to that of A549 cell lysates, loaded at equivalent concentrations. Of note, this blot was cut in order to place the A549 exosomes and A549 cell lysates side by side. Here we observed the exosome positive control Flotillin-2 is in the exosome sample, however at a lower concentration then that of the cell lysate. The negative exosome markers were not detectable in the exosome sample, but were present in the A549 cell lysate. Lastly Flotillin-2 was used to confirm no vesicles remained in the media following exosome collection, which suggested complete particle harvest, Figure 4.3E. Overall, although the harvested exosome samples may not be pure, exosomes represent a large proportion of the microvesicles collected.

The next step was to determine if exosomes represent a mechanism for SMN release. These newly acquired exosomes were investigated via immunoblot for the presence of SMN.
Figure 4.3 Size of harvested exosomes and detection with various markers.

Panel A: Particle size as determined via Nanosight. A549 exosomes purified through ultracentrifugation including a 10,000 xg centrifugation step.

Panel B: Particle size as determined via Nanosight. A549 exosomes purified through ultracentrifugation including a 0.2 µm filtration step. This method of purification was done for all following exosome experiments unless otherwise stated.

Panel C: Harvested A549 (2.4µg) and 293 (0.15µg) exosomes were separated by SDS-PAGE, and the resulting immunoblot probed for the positive exosome marker ALIX. Exosome concentration was determined by Bradford assay with non-lysed samples. Data represents n=3.

Panel D: Exosomes from A549 cells and A549 cell lysates were diluted to a concentration of 15µg/mL and separated by SDS-PAGE. The immunoblot was probed with the positive exosome marker Flotillin-2 and the negative exosome markers SMAC and Calnexin. Exosome and cell lysate concentrations were determined using Bradford assay with lysed samples. Data represents n=2.

Panel E: TCA precipitation was performed on A549 media post exosomes collection. This vesicle-free media was subject to SDS-PAGE and immunoblot with Flotillin-2. TCA precipitated media from A549 cells infected with Ad-SMN at MOI 100 for 24 hours was used as a positive control. Data represents n=2.
Figure 4.4A showed that SMN is detectable in all particles isolated during exosome purification. Furthermore, it was determined that SMN is detectable in exosomes harvested from different cells lines including A549, 293, and HUVEC, Figure 4.4B. Differences in SMN levels suggest exosomes produced from different cell lines vary in protein content, which agrees with current literature. Together this indicates that SMN is naturally found in exosomes and this can function as a method for SMN release from cells.

We next investigated if we could increase the quantity of SMN in exosomes, using two different approaches. First, a new cell line which over expresses Flag-SMN, A549::SMN, was created from A549 cells by cloning and nucleofection. Figure 4.5 showed this new A549::SMN cell line overexpresses SMN relative to the parental A549 cell line in cell lysates (A), media following TCA precipitation (B) and harvested exosomes (C). The N-terminal Flag tag was also detectable in cells via immunoblot and immunofluorescence. The cells were examined by immunofluorescence to determine the cellular localization of the SMN protein. Figure 4.6 showed that the Flag-SMN was found inside as well as surrounding the nucleus, which is in agreement with native SMN [61]. The Flag tag was also detectable in A549::SMN exosomes (bottom panel of Figure 4.5C), however the Flag signal is much weaker then that of the SMN signal suggesting the Flag tag is being modified. The second method to enhance the amount of SMN in exosomes was to infect A549 cells with an Ad vector expressing Flag-SMN, Ad-SMN (Figure 4.1). A549 cells were infected at a MOI 50 and incubated for 24 hours prior to exosome harvest. Infection with Ad-SMN resulted in enhanced amounts of SMN as well as the presence of the Flag tag in cells (Figure 4.7A), media precipitates (B) and exosomes (C). Again, detection of the Flag tag appeared to be reduced as the signal in media was significantly lower compared to SMN and the Flag signal in the exosome sample was sporadic and unreliable. Overall it was determined that SMN is
Figure 4.4 *SMN is present in microvesicles, including exosomes, from various cell lines.*

Panel A: Vesicles from HUVEC by Dr. Dylan Burger were collected at each step of the exosome purification protocol. HUVEC samples were lysed and stored in RIPA buffer. Five µg of each sample was separated by SDS-PAGE and probed for SMN. Concentrations were determined using a Bradford assay. Data represents n=2.

Panel B: Exosomes harvested from A549 (2.4µg) and 293 (0.15µg) cells were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN and ALIX. Exosome concentration was determined using Bradford assay with non-lysed samples. Top panel is the same as Figure 4.3C. Data represents n=3.
**Figure 4.5** *SMN expression can be enhanced in exosomes using an SMN-over expressing cell line.* A new cell line A549::SMN was created from A549 cells, which over expresses Flag-SMN through hygromycin selection.

Panel A: A549 and A549::SMN cells were lysed in 2x LD and separated by SDS-PAGE. The resulting immunoblot was probed for SMN, tubulin and Flag. Equivalent volumes of cell lysates were used. Data represents n=3.

Panel B: A549 and A549::SMN TCA media precipitates were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN. Equivalent volumes of TCA precipitate were applied to the gel. Data represents n=3.

Panel C: 0.5µg of both A549 and A549::SMN exosomes were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN, Flag and ALIX. Exosome concentration was determined using a Bradford assay with non-lysed samples. Data represents n=3.
Figure 4.6 A549::SMN cells express Flag tagged SMN. A549 and A549::SMN cells were examined by immunofluorescence using both Hoechst (left) and Flag (middle). Images were merged (right) to determine cellular localization of Flag-SMN. Data represents n=3.
Figure 4.7 *The level of SMN protein is enhanced in exosomes isolated from Ad-SMN infected cells.*

A549 cells were infected at an MOI of 10, 50 or 100 with Ad-SMN (or mock infected), 24 hpi cells were harvested and media was collected for TCA precipitation or in the case of MOI 50 media was collect for exosome purification.

Panel A: A549 or Ad-SMN infected A549 cells were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN, tubulin and Flag. Equivalent volumes of cell lysate were applied to the gel. Data represents n=3.

Panel B: A549 or Ad-SMN infected A549 TCA media precipitates were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN and Flag. Equivalent volumes of TCA precipitate were applied to the gel. Data represents n=3.

Panel C: A549 or Ad-SMN infected A549 exosomes were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN and ALIX. 2.4µg of A549 and 2.8µg of A549::SMN exosomes were applied to the gel. Exosome concentration was determined using a Bradford assay with non-lysed samples. Data represents n=3.
contained within exosomes and the level of SMN protein can be enhanced through genetic modification or viral infection. Of note, the Flag tag used for tracking SMN appears to be less readily detectable in exosome samples versus samples isolated from cells.

4.2.b Exosomes associate with recipient cells

In order to act as a therapeutic it is essential that SMN-containing exosomes are able to enter recipient cells and this newly acquired SMN must be functional. Exosome entrance was tested through a variety of different means. Each process involved incubating 5 µg A549::SMN exosomes on recipient A549 cells for approximately 4 hours at 37°C. Immunoblot was preformed to determine if Flag-SMN associates with the recipient cells. Figure 4.8 showed that there is a unique Flag signal in the A549::SMN exosome treated recipient cells. This flag signal indicates our harvested exosomes are able to successfully attach to other cells. Immunofluorescence was used to confirm exosome entrance as well as determine cellular localization of the protein. Unfortunately, we were unable to detect a flag signal in recipient cells, but it is unclear if this is due to lack of entry of the exosomes or poor Flag signal, as shown above. To further explore this issue, a Co-IP was preformed to determine if Flag-SMN from delivered exosomes interacted with its normal cellular components. The pull down was preformed with Flag to isolate exosome-derived SMN and association with the normal cellular partner Gemin-2 was analyzed via immunoblot. Unfortunately again the weak Flag signal compromised our ability to obtain a clear answer (data not shown). Overall Flag-SMN is able to associate with recipient cells; however, further experiments are needed to determine whether the exosomes are capable of delivering SMN to the interior of the cell.
Figure 4.8 *Exosomes associate with A549 recipient cells.* 5 µg A549::SMN exosomes were incubated on recipient A549 cells for 4 hours then harvested using 2x LD. Cell lysates were separated by SDS-PAGE, and the resulting immunoblot was probed for Flag. A non-specific flag signal is detectable in all samples. Pan-actin was used as a loading control. Data represents n=2.
SMN is found in exosomes isolated from mouse serum

The first step for *in vivo* studies was to determine if exosomes could be harvested from murine serum. Exoquick was used to concentrate exosomes instead of ultra centrifugation as it is effective with very small volumes. Exoquick functions through a key polymer decreasing available water molecules forcing less-soluble components like vesicles to precipitate out of solution [59]. Following the Exoquick protocol, serum derived exosomes were analyzed via Nanosight Tacking analysis, Figure 4.9B. Due to the high concentration of the particles, significant levels of background noise were observed. However, the mean particle size, 105 nm, was smaller than achieved from the *in vitro* harvested exosomes. Next, the exosome samples were tested for the positive exosome marker Flotillin-2 by immunoblot. Figure 4.9A showed the presence of Flotillin-2 in the serum sample suggesting the pellet acquired from Exoquick does represent exosomes. We next investigated whether SMN was contained within these exosomes and therefore normally released from cells *in vivo*. We observed that SMN was found within the serum derived exosomes and this signal was enhanced in exosomes relative to that of pure serum, Figure 4.10B. Also surprising was the difference in endogenous SMN expression levels between homogenized liver and spinal cord, where the spinal cord expressed approximately 10x more SMN when equal quantities of protein were applied to the gel, Figure 4.10A. This finding agrees with previous literature suggesting different tissues may vary in their SMN levels and thresholds. Overall, this agrees with our *in vitro* data suggesting natural release of SMN. The fact that SMN is normally found circulating in the body lends support to the overall projects goal to use the liver as a SMN production factory.
Figure 4.9 Isolation of serum-derived exosomes.
Panel A: Media incubated on A549 cells for 24 hours was subjected to Exoquick to be comparable to serum derived exosomes. Equivalent volumes of exosomes derived from media and serum were separated by SDS-PAGE, and the resulting immunoblot was probed for Flotillin-2. Data represents n=2.
Panel B: Particle size as determine via Nanosight. Serum exosomes were purified through Exoquick for all experiments.
Figure 4.10 *Endogenous SMN is detectable in tissues and serum.*

Panel A: Six to eight week old C57Bl/6J mice liver and spinal cord samples were homogenized and 15µg of protein was separated by SDS-PAGE. The resulting immunoblot was probed for SMN and GAPDH as a loading control. Of note, the IgG heavy chain is also detectable. Data represents n=3.

Panel B: C57Bl/6J mouse serum and serum exosomes were separated by SDS-PAGE, and the resulting immunoblot was probed for SMN. Equivalent volumes were applied to the gel. Note the IgG heavy chain is also detectable. Data represents n=3.
4.2.c Virally-derived β-gal can be loaded into exosomes in vivo

Now that serum exosomes can be harvested, the Ad5LlacZ construct from Chapter 3 was used to determine if virus-derived proteins could be loaded within these exosomes. Ad5LlacZ was chosen due to its high β-gal expression and the ease of β-gal detection. The virus was delivered to six to eight week old CD1 mice at a high viral dose, $5 \times 10^{12}$ VP/kg, via IV injection. Mice were then euthanized 24 hours later by cardiac puncture and chest opening to allow for maximum blood collection. Exosomes were harvested by Exoquick and analyzed via chemiluminescence assay (Applied Biosystems) and immunoblot in 2x LD. For comparison A549 cells were infected with Ad5LlacZ at MOI 50, the concentration used for all in vitro exosome preparations. Twenty-four hpi, the media was collected and exosomes harvested using the corresponding media Exoquick protocol. Figure 4.11A shows that β-gal is present in Exoquick derived exosomes isolated from both cells and serum when analyzed by chemiluminescence assay. The difference in β-gal expression relative to the PBS controls was considerably larger for cellular-derived exosomes than serum derived exosomes. This difference was also reflected in the immunoblot experiments where β-gal was detectable in cellular-derived exosomes, Figure 4.11B, but no significant signal in serum-derived exosomes was observed compared to the PBS control, Figure 4.11C. Together these results suggest that virally produced proteins are present in serum exosomes but at very low levels, levels below the sensitivity of western blot.

4.2.d Virally-derived SMN is undetectable in serum exosomes with anti-Flag

Finally, we investigated whether viral derived SMN could be detected in serum exosomes. Six to eight week old C57Bl/6J or CD1 mice were treated with $5 \times 10^{12}$ VP/kg of Ad-SMN through an IV injection. After a 24 hour exposure period, several tissues were
Figure 4.11 Virally produced β-gal is detectable in both cellular- and serum-derived exosomes.

A549 cell were infected with Ad5LlacZ at an MOI 50 or mock infected. Twenty-four hpi media was collected and exosomes harvest via Exoquick. Six to eight week old CD1 mice were injected with Ad5LlacZ or PBS at a concentration of 5x10^{12} VP/kg via IV injection. Twenty-four hours post injection mice were sacrificed by cardiac puncture and serum exosomes harvest using Exoquick.

Panel A: β-gal expression of exosomes derived from serum from mice treated with or cells infected with Ad5LlacZ was assessed by chemiluminscent assay. Data represents n=1-2.

Panel B: Exosomes isolated from A549 or Ad-SMN infected A549 were separated by SDS-PAGE and the resulting immunoblot was probed for β-gal. Data represents n=2.

Panel C: Serum derived exosomes from mice treated with Ad5LlacZ were separated by SDS-PAGE and the resulting immunoblot was probed for β-gal. Equivalent volumes of serum exosomes were applied to the gel. Data represents n=2.
removed and serum collected by cardiac puncture. Tissues were homogenized, subjected to immunoblot and probed for both SMN and Flag. While Ad-SMN liver samples showed significantly enhanced SMN expression relative to the control mice, Figure 4.12A, the difference in Flag expression in the same 3 Ad-SMN infected mice was not nearly as dramatic, Figure 4.12B. For example, in the middle lane of Figure 4.12B the Ad-SMN injected mouse had no detectable Flag signal, the reason for this is unknown however, it is thought to be a result of the Flag tag being altered. The TA muscle, diaphragm and spinal cord were also examined although none had any detectable Flag expression or change in SMN levels (data not shown). Lastly serum exosomes were tested for the presence of SMN derived from Ad-SMN however as expected no Flag signal was detectable (data not shown). Nor did serum exosomes yield any enhancement in SMN levels, Figure 4.12C. Next, we examined whether increasing the time before isolation of the exosomes from the mice could result in enhanced levels of SMN in the exosomes. The experiment was repeated with cardiac puncture taking place 72 hours post injection. The expression profiles are consistent with that of the 24 hour incubation. The liver still contained high SMN levels, Figure 4.12D, with marginal Flag expression, Figure 4.12E, while the TA muscle, diaphragm, spinal cord and serum exosomes had no change in SMN levels (Figure 4.12F) or detectable Flag signal (data not shown). The lack of enhanced SMN levels in serum exosomes suggests that SMN derived from the Ad vector is not being efficiently packaged into exosomes or possibly liver exosomes do not represent a large proportion of the exosomes in the circulatory system or detection issues. Further studies must be done to ensure that (1), virally transcribed SMN can be packaged into exosomes and (2), the liver functions to release a significant proportion of the circulating exosomes.

We also examined whether changing the tag contained on the SMN protein may
Figure 4.12 In vivo Ad-SMN injection results in elevated SMN levels in the liver but not in serum-derived exosomes. Six to eight week old mice were treated with Ad-SMN or PBS at a concentration of $5 \times 10^{12}$ VP/kg via IV injection. After 24 hours (C57Bl/6J mice) or 72 hours (CD1 mice), mice were sacrificed by cardiac puncture. Tissues were removed, homogenized and serum exosomes were harvest using Exoquick.

Panel A: Liver samples from mice subjected to a 24 hour incubation period were homogenized and 20µg of protein was separated by SDS-PAGE. The resulting immunoblot was probed for SMN. Data represents n=3.

Panel B: Liver samples from mice subjected to a 24 hour incubation period were homogenized and 20µg of protein was separated by SDS-PAGE. The resulting immunoblot was probed for Flag. Data represents n=3.

Panel C: Serum exosomes from mice subjected to a 24 hour incubation period were separated by SDS-PAGE and the resulting immunoblot was probed for SMN. Equivalent volumes of serum exosomes were applied to the gel. Data represents n=3.

Panel D: Liver samples from mice subjected to a 72 hour incubation period were homogenized and 20µg of protein was separated by SDS-PAGE. The resulting immunoblot was probed for SMN. Data represents n=2.

Panel E: Liver samples from mice subjected to a 72 hour incubation period were homogenized and 20µg of protein was separated by SDS-PAGE. The resulting immunoblot was probed for Flag. Data represents n=2.

Panel F: Serum exosomes from mice subjected to a 72 hour incubation period were separated by SDS-PAGE and the resulting immunoblot was probed for SMN. Equivalent volumes of serum exosomes were applied to the gel. Data represents n=3.
allow for detection of virus-derived SMN in serum exosomes. Six to eight week old CD1 mice were injected under the same conditions as described above with Ad-SMN-myc-his, a viral vector containing SMN and the following tags: N-terminal Flag and C-terminal myc-his (Figure 4.1A). Twenty-four hours after injection, mice were euthanized, serum collected and exosomes purified through Exoquick. Immunoblot was preformed with the serum exosomes; however neither myc nor his antibodies resulted in a significant signal over background, Figure 4.13. Taken together these results indicate that endogenous SMN is naturally contained within exosomes isolated from serum. Furthermore, Ad-SMN was able to enhance SMN levels within the liver however; low proteins levels make detection of virally-derived SMN in serum exosomes inconclusive.
**Figure 4.13** Myc and his tags contained on Ad-SMN-myc-his are not detectable in serum exosomes. CD1 mice were injected with Ad-SMN-myc-his or PBS at a concentration of 5x10^{12} VP/kg via IV injection. Twenty-four hours post injection mice were euthanized and exosomes collected via Exoquick. Serum derived exosomes were separated by SDS-PAGE and the resulting immunoblot was probed for myc (Panel A) or his (Panel B). Equivalent volumes of serum exosomes were applied to the gel. Data represents n=2.
4.3 Discussion

4.3.a Overview

It was determined in Chapter 3 that the reduced virion size of the modified Ad vectors were unsuccessful at enhancing infection of spinal cord or skeletal muscle. However, as observed in many studies, we detected high-level uptake in liver. This observation suggested that one approach might be to use the liver as a protein production factory, as has been used successfully for other systemic diseases such as hemophilia [113]. The goal of this chapter was to produce an SMN protein that was able to spread systemically. Following Ad-SMN vector liver infection, significant amounts of the virally encoded SMN will be transcribed. In this study it was determined that SMN can be released naturally from cells through means of microvesicles. Exosomes can enter and deliver proteins to recipient cells suggesting this approach may be appropriate for treatment of SMA.

4.3.b Microparticle contamination

Exosomes were harvested using an established protocol [103] and analyzed via Nanosight. Nanosight relates the rate of Brownian motion to particle size [25]. However, we observed that the mean particle size was larger than expected for a pure exosome population. This may be a result of technical issues with evaluating the samples as the Nanosight used was not on an air table or in an isolated area. Regardless, the Nanosight set-up cannot fully explain the large particle size. As such, it was thought that the exosome sample might be contaminated with microparticles. Microparticles are larger than exosomes with a size range between 100-1000 nm and bud from the plasma membrane instead of MVB [101]. Fortunately both exosomes and microparticles share a role in cell-to-cell communication [25], therefore microparticles will not hinder the overall goal of systemic SMN delivery.
Nevertheless, steps were taken to increase the purity of the exosome sample by changing the method of purification from a 10,000 xg centrifugation step to filtration through a 0.2 µm membrane (Figure 4.3). Although this approach resulted in some success, the microparticle contamination was not eliminated. Other studies have shown that size readings from Nanosight are slightly larger than the reported exosome size; for example, exosomes harvested by Ramteke et al had a Nanosight reading of 141-187 nm while electron microscopy suggested the exosomes were 50-100 nm [86]. Differences in size readings from these two methods may be a result of particle aggregation [86]. Taken together we believe our harvested particles do represent a relatively pure exosome population.

4.3.c Exosome yield

Studies have shown that 1-2 µg of exosomes can be harvested from $10^6$ immature dendritic cells, where dendritic cells are known to produce very high quantities of exosomes [103]. Our harvested exosomes preparation, however, gave lower yields of only 1 µg per 2.4x$10^6$ A549 cells, approximately half as much. This was surprising as the exosome collection protocol used is well established and had fewer steps than other protocols, hence a decreased risk of sample loss [33]. One possible reason for this difference is that A549 cells, used in the majority of this study, are not an ideal cell type for studying exosomes. It is known that cells release over six times more exosomes in suspension than when attached to a plate [53]. This was shown by Koumangoye et al, who demonstrated that the addition of EDTA, to detach adherent cells, resulted in abundant exosome release [53]. With this in mind, exosomes could be harvested from 293N3S cells or another cell line in suspension to increase exosome yield. Therefore future studies should use cells in suspension or a non adherent liver cell line which would be more physiologically relevant.
4.3.d **Exosome markers**

Several different exosome markers were used to test the harvested particle samples (Figure 4.3). Positive controls include proteins more commonly found within exosomes, which are proteins involved in vesicle development and transport. Negative exosome markers are endoplasmic reticulum or mitochondrial based proteins that have minimal interactions with a forming MVB. Unfortunately, due to the process of exosome formation the presence of a positive exosome markers does not confirm the particle is actually an exosome. As well, since cytosolic proteins can be captured in exosomes, it is possible, though rare, for negative exosome markers to be found within exosomes. Overall, appropriate or definitive controls for exosome detection are lacking and need to be developed to further the exosome research field.

4.3.e **SMN containing exosomes *in vitro***

We were fortunate to detect SMN within exosomes, indicating no modifications were necessary for the protein to be packaged into these structures. This is not uncommon of cytosolic proteins [104, 33]. We were also able to demonstrate that when SMN is over expressed within the cell there is an enhancement of the protein within exosomes. Overall, these findings suggest that SMN is naturally released from cells in exosomes and the amount of SMN within the exosomes can be altered through viral vectors. Of note, it was also found that SMN was released in apoptotic bodies and microparticles; however, due to the small size of our harvested microvesicles we believe that SMN is released from live cells and is not just an artefact of cell death represented by apoptotic bodies.
4.3.f  **Exosome-mediated delivery of proteins to recipient cells**

For our therapeutic strategy to be successful it is vital for hepatocyte-derived exosomes to enter recipient cells, principally α-motor neuron and skeletal muscle, the damaged tissues in SMA. Immunoblot results suggest our SMN-containing exosomes are able to associate with recipient A549 cells (Figure 4.8). However, both immunofluorescent and Co-IP experiments proved unsuccessful at showing detectable levels of exosome-delivered SMN within recipient cells. Studies have shown that exosome entrance can be as efficient as transfection [2], though this was demonstrated using immune recipient cells, known to be superior at exosome up-take [62]. Our low levels of association may be a result of two factors: (i) exosomes remaining attached to the outer cell surface and (ii) a weak Flag signal. Throughout this chapter, issues with Flag detection has occurred, compromising our ability to effectively track exosomes. It is thought that a post-translational modification must be occurring to result in this loss of signal. Previous studies by Schmidt et al have shown that the tyrosine at position two in the Flag tag is highly susceptible to tyrosine sulfation in insect cells and this significantly abolishes Flag-anti-Flag interactions [96]. Although the means of post-translation modification occurring within our cells remains unknown, it is thought to significantly reduce the efficiency of detection of the Flag tag.

Until further experiments are preformed to determine the success of exosome up-take, the functionality of the delivered SMN cannot be properly assessed. It is believed that the delivered SMN protein will be functional as studies have shown exosomes are able to deliver functional mRNA [112]. Thus once the SMN tags are optimized exosome entrance and protein function can be more accurately assessed.
4.3.g **Detection of virus derived SMN in vivo**

The Ad-SMN viral vector could be used directly to treat SMA patients, as the Ad vector is deleted of essential viral genes (E1 and E3), preventing viral replication. Following infection, virally derived SMN could be packaged into exosomes which would then spread throughout the body. Due to significant localization of Ad to the liver, detection of both enhanced SMN levels and the Flag tag were possible in the liver at both 24 and 72 hours post-treatment (Figure 4.12). However, the difference in expression between Flag and SMN suggests the Flag tag is again being modified. No elevation of SMN or detection of the Flag tag was observed in serum exosomes following Ad-SMN delivery to mice. Yet, this was expected as initial experiments with β-gal-expressing viruses indicated that immunoblot experiments were not sensitive enough to detect low levels of virus-derived proteins contained in the exosomes (Figure 4.11). Other tags were tested, *i.e.* myc and his, yet they too were unsuccessful at tracking SMN derived from the Ad vector *in vivo* (Figure 4.13). Regardless, it is expected that the SMN protein is present in serum exosomes at very low levels, well below the detection limits of western blot.

4.4 **Conclusion**

SMN is naturally released and carried within exosomes from a variety of cell lines and *in vivo*. This is important in the treatment of SMA where the lack of SMN in α-motor neurons and skeletal muscle results in muscle deterioration and death. Using SMN over expressing cells or Ad vectors, the amount of SMN within exosomes can be enhanced, leading to a possible SMA therapeutic.
Chapter 5 – Overview of SMA treatments

5.1 Summary

Ad has great potential as a viral vector for gene therapy due to its high safety profile and its large cloning capacity [116]. Current studies have shown that helper-dependent Ad has the ability to persist and express a transgene \textit{in vivo} for extended time periods, up to at least 7 years in non-human primates [12]. Thus Ad vectors are an ideal therapeutic for SMA, a progressive disease caused by insufficient levels of the SMN protein. Disease onset occurs early in life and is seen as deterioration of the $\alpha$-motor neurons and skeletal muscle.

Given that Ad predominately localizes to the liver the initial goal was to enhance vector spread through decreasing the overall size of the virion. The virion diameter was reduced through producing a chimeric Ad5 vector with an Ad9 shaft, as the Ad9 shaft is roughly one third the length of an Ad5 shaft. Additional modifications to the chimeric vector included addition of 7 lysine residues to enhance interactions with heparan sulphate proteoglycans while also increasing the overall virion charge. Unfortunately, neither modification resulted in enhanced systemic spread. All viral constructs localized to the liver or remained at the site of injection. Although infection, determined via transgene expression, was detected in both the desired tissues, the $\alpha$-motor neurons and skeletal muscle, the lack of viral spread suggests that multiple injections would be required to prevent deterioration of each muscle group. As such, further modifications to Ad vectors are needed to achieve efficient systemic biodistribution of Ad.

Preliminary experiments indicated that SMN is found outside the cell. Follow-up studies determined that this is a result of SMN release in microvesicles. Exosomes, a type of microvesicle which functions in cellular communication, are released from cells under normal conditions, travel throughout the body and are taken up by recipient cells. This
observation led to the second goal of using exosomes to achieve systemic biodistribution of the SMN protein produced from an SMN-expressing Ad vector. It was found that SMN is contained in all microvesicles including exosomes and SMN levels could be enhanced within exosomes. Unfortunately due to issues with the Flag tag used to track vector-derived SMN, it could not be determined if SMN associating with recipient cells was able to enter the nucleus or function properly. It was also not possible to determine if vector derived SMN was contained in exosomes \textit{in vivo}. However vector-derived β-gal was detectable in serum exosomes by chemiluminescence as such it is likely that virally-derived SMN is present in serum exosomes as well. This project has great promise and investigations are still ongoing.

5.2 \textbf{Future directions}

All viruses tested in Chapter 3 were able to infect both α-motor neurons and skeletal muscle, yet were unable to spread within these tissues in any capacity. We therefore suggest that additional approaches should be examined to further modify the fiber protein until enhanced viral spread is achieved. These modifications include further altering the size of the Ad virion, increasing the number of poly-lysine residues and decreasing the tropism to CAR. Exchanging the Ad5 shaft with an Ad9 decreased the virion size by approximately 50 nm however this did not result in enhanced viral spread. Other chimeric vectors could be explored to determine if the Ad size can be further reduced allowing for greater spread \textit{in vivo}. Increasing the number of poly-lysine residues could result in two benefits (1) amplify interactions with mature muscle tissue and other cells with low CAR expression and (2) increase the overall charge of the virion, thereby decreasing the repulsion from the negative cell membrane. Finally, action could be taken to abolish fiber’s specificity to CAR. This would result in the virus relying on alternate primary or secondary interactions, such as
penton, to associate with host cells. These interactions may occur more slowly, increasing the amount of time the vector is free-floating throughout the body and potentially enhancing systemic spread.

The project discussed in Chapter 4, Exosome transport of SMN, remains ongoing with several avenues yet to be investigated. First, experiments could be done to enhance SMN within exosomes. This may be possible through the addition of a C1C2 lactadherin domain. Studies have shown the C1C2 domain results in higher rates of exosome packaging due to the formation of high affinity complexes between the C1C2 domain and membranes, including MVB [39]. Second, experiments could be done to improve exosome entrance in recipient cells. Exosomes could be modified with targeting ligands, such as Nerve Growth Factor, known to interact with the Trk family of neurotrophin receptors expressed on motor neurons [4]. These receptors could assist not only in exosome uptake but also enhance uptake in desired tissues, as demonstrated previously by Alvarez et al [2]. Lastly, although we believe SMN derived from Ad-SMN is packaged in exosomes in vivo this was not confirmed due to the detection limits of western blot. Additional experiments with increased detection specificity must be done to determine if Ad-SMN enhances SMN levels in serum exosomes. Sanchez et al suggested SMN interacts with translational machinery affecting some mRNAs including CARM1 [43], as such a functional assay involving serum exosomes and CARM1 could be done to functionally determine changes in SMN levels.

Alternatively, instead of loading exosomes with SMN through an Ad-vector, exosomes could be harvested from an individual and the SMN protein directly loaded or attached, as observed in current clinical trials [112]. This approach would involve the isolation and purification of human exosomes which are then modified through attaching the desired protein to the exterior of the exosome. These loaded exosomes are then reintroduced
into the original donor. Unfortunately this type of exosome treatment has two drawbacks (i) it must be done on an individual basis to prevent immune reactions and (ii) this requires isolation and purification of large quantities of the desired SMN protein, a process for which is still being established.

5.3 Conclusions

Overall, it was found that body-wide distribution of the Ad constructs tested was not achieved even with significantly reduced virion size. However, we determined that SMN is naturally release from cells in exosomes and protein levels can be enhanced through Ad vectors. Experiments are ongoing to determine if SMN-expressing Ad vectors can be used in conjunction with exosomes for systemic protein spread and the treatment of SMA.
6. References


7. Appendix 1 – Chemicals and Reagents

Cell culture
- Complete medium: MEM or DMEM (Life Technologies)
  - 10% FBS (Sigma)
  - 1% antibiotic/antimycotic (Life Technologies)
    - 0.1 mg/ml streptomycin and 100 U/ml penicillin
  - 1% glutamax (Life Technologies)
- Differentiation medium: DMEM (Life Technologies)
  - 2% horse serum (Life Technologies)
  - 1% antibiotic/antimycotic (Life Technologies)
  - 1% glutamax (Life Technologies)
- Hygromycin medium: MEM (Life Technologies)
  - 10% FBS (Sigma)
  - 150 mg hygromycin (Invitrogen)
  - 1% antibiotic/antimycotic (Life Technologies)
  - 1% glutamax (Life Technologies)
- Unmodified MEM: MEM (Life Technologies)

- 10x Citric Saline: 1.35 M KCl (Fisher)
  - 150 mM sodium citrate (Fisher)
  - In ddH₂O, autoclave 45 minutes at 121°C
- 1x Citric Saline: 50 mL 10x citric saline in 500 mL ddH₂O
- 1x Trypsin: 20 mL 10x Trypsin (Life Technologies)
  - In 200 mL PBS (Sigma)

Particle count
- Assay solution: 1 mM EDTA, (Fisher)
  - 0.1% SDS (Fisher)

TCA media precipitation
- 100% Trichloroacetic acid (Sigma-Aldrich)

Tissues
- RIPA buffer: 0.5% sodium deoxycholate (Fisher)
  - 100 mM NaCl (Fisher)
  - 50 mM Tris pH8 (Fisher)
  - 0.1% SDS (Fisher)
- 20% PFA stock: 20% PFA in RNAse-free H₂O (BDH)
- 2% PFA fixative: - 10 mL of 20% PFA
  - 81 mM Na₂HPO₄ (Sigma-Aldrich)
  - 19 mM NaH₂PO₄ (Sigma-Aldrich)
  - 2 mM MgCl₂ (BDH)
  - 1.25 mM Ethylene glycol tetraacetic acid pH 7.4 (Sigma-Aldrich)

- X-gal Stain: - 39 mL X-gal wash buffer
  - 4% X-gal stock (Fisher)
  - 0.2% Potassium ferrocyanide (BDH)
  - 0.15% Potassium ferricyanide (BDH)

- X-gal wash buffer: - 2 mM MgCl₂ (BDH)
  - 1% sodium deoxycholate (Fisher)
  - 2% NP-40 (GBioSciences)
  - 97.8 mM Phosphate buffer

- Phosphate buffer: - 23 mM Na₂HPO₄ (Sigma-Aldrich)
  - 77 mM NaH₂PO₄ (Sigma-Aldrich)

**Immunofluorescence**
- 4% PFA fix: - 4% formaldehyde (Sigma-Aldrich)
  - In PBS

- BSA Blocking buffer:
  - 0.5% BSA (Sigma)
  - 0.4% Triton X-100 (Fisher)
  - In PBS

**Western Blot**
- 2x Laemmli loading dye (LD): - 62.5 mM Tris-HCl pH6.8 (Fisher)
  - 25% glycerol (Fisher)
  - 2% SDS (Fisher)
  - 0.01 g bromophenol blue (EM Science)
  - 5% β-mercaptoethanol (Fisher)

- Stacking Solution: - 50% 2x Stacking Buffer
  - 3.75% Acrylamide (Fisher)
  - 0.016% Ammonium persulfate (Fisher)
  - 0.16% N,N,N',N'-tetramethylethylenediamine (Sigma-Aldrich)
  - In ddH₂O

- 2x Stacking Buffer: - 250 mM Tris-HCL pH 6.8 (Fisher)
  - 0.2% SDS (Fisher)
• 12% Separating Solution: - 49.5% 2x Separating Buffer
  - 8.9% Acrylamide (Fisher)
  - 0.09% Ammonium persulfate (Fisher)
  - 0.1% N,N,N’,N’-,tetramethylethylenediamine (Sigma-Aldrich)
  - In ddH₂O

• 15% Separating Solution: - 49.5% 2x Separating Buffer
  - 11.2% Acrylamide (Fisher)
  - 0.09% Ammonium persulfate (Fisher)
  - 0.1% N,N,N’,N’-,tetramethylethylenediamine (Sigma-Aldrich)
  - In ddH₂O

• 2x Separating Buffer: - 750 mM Tris-HCl pH 8.8 (Fisher)
  - 0.2% SDS (Fisher)

• Running Buffer: - 1.44% glycine (Fisher)
  - 0.1% SDS (Fisher)
  - 50 mM Tris-HCl (Fisher)

• Transfer Buffer (Semi Dry): - 0.293% glycine (Fisher)
  - 20% MeOH (Fisher)
  - 0.0375% SDS (Fisher)
  - 48 mM Tris-HCl (Fisher)

• Wash buffer (0.1% TBST): - 0.1% TWEEN-20 (Fisher)
  - 150 mM NaCl (Fisher)
  - 10 mM Tris-HCl pH 8.0 (Fisher)

• Milk Blocking Solution: - 5% skim milk powder
  - In 0.1% TBST
A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice

Emily R. McFall a,b, Lyndsay M. Murray a,1, John A. Lunde c, Bernard J. Jasmin c,d, Rashmi Kothary e,f,g, Robin J. Parks a

a Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada K1H 8L6
b Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
c Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada
d University of Ottawa Centre for Neuromuscular Disease, Ottawa, Ontario, Canada
e Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

A R T I C L E   I N F O

Article history:
Received 17 June 2014
Returned to author for revisions
28 July 2014
Accepted 22 August 2014
Available online 20 September 2014

Keywords:
Adenovirus
Transduction
Viral vector
Muscle

A B S T R A C T

We have investigated whether reducing the overall size of adenovirus (Ad), through use of a vector containing a shortened fibre, leads to enhanced distribution and dissemination of the vector. Intravenous or intraperitoneal injection of Ad55lacZ (12 nm fibre versus the normal Ad5 37 nm fibre) or Ad585PklacZ (shortened fibre with polylysine motif in the H–I loop of fibre knob domain) led to similar levels of lacZ expression compared to Ad55lacZ (native Ad5 fibre) in the liver of treated animals, but did not enhance extravasation into the tibialis anterior muscle. Direct injection of the short-fibre vectors into the tibialis anterior muscle did not result in enhanced spread of the vector through muscle tissue, and led to only sporadic transgene expression in the spinal cord, suggesting that modifying the fibre length or redirecting viral infection to a more common cell surface receptor does not enhance motor neuron uptake or retrograde transport.

© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Introduction

Human adenovirus (Ad) is the most common platform for delivery of therapeutic genes in gene therapy applications, and has been used in approximately 23% of all human clinical trials to date (Gimm et al., 2013). Ad has many advantages that have allowed it to become so widely utilised. Deletion of the Ad early region 1 (E1) renders the vector replication defective and together with additional deletion of the non-essential E3 region provides a relatively large cloning capacity of ~8 kb (Bett et al., 1993). Ad vectors devoid of all viral protein sequences, termed helper-dependent Ad (Palmer and Ng, 2005; Parks et al., 1996), further increase this cloning limit to ~36 kb (Parks and Graham, 1997). Ad vectors remain predominantly episomal in transduced cells (Harui et al., 1999; Hillenberg et al., 2001; Jager and Ehrhardt, 2009; Stephen et al., 2010; Wong et al., 2013), greatly reducing the risk of insertional inactivation or activation of cellular genes. Ad has a relatively good safety profile (Anhaltfano and Parks, 2003), although at very high doses Ad can cause acute inflammation and toxicity, which can be lethal (Brunetti-Pierri et al., 2004; Morrall et al., 2002; Raper et al., 2003). Upon systemic delivery in most species, human Ad serotype 5 (the most commonly used subtype) preferentially accumulates in the liver (Gao et al., 1996; Nicol et al., 2004; Worzall et al., 1997). This preferential uptake in the liver is due in part to the physical architecture of this tissue (Ad becomes trapped in the liver sinusoids and fenestrations (Bernt et al., 2003; Ross and Parks, 2003)), and the rapid scavenging of Ad vectors by Kupffer cells in the liver triggers a robust pro-inflammatory cytokine response (Lieber et al., 1997; Munave et al., 1999). A unique mechanism of Ad5 uptake in liver hepatocytes also contributes to Ad-induced inflammation. The Ad5 hexon protein interacts with coagulation factor X which provides a bridging interaction for binding to heparan sulphate proteoglycans expressed on the surface of hepatocytes, allowing internalisation (Alba et al., 2012; Brashaw et al., 2010; Kalyuzhny et al., 2008; Waddington et al., 2008). Detection of internalised Ad-associated factor X by toll-like receptor 4 in the endosome triggers an innate immune response and inflammatory signalling (Doronin...
et al., 2013). However, Ad vectors containing mutations in the hexon protein that prevent its interaction with factor X, still localise to the liver, although uptake by hepatocytes is dramatically reduced (Alha et al., 2010; Kalyuzhnyi et al., 2008). These results suggest that physical constraints, other than receptor binding, contribute significantly to vector biodistribution.

The virion of Ads is a non-envelopedicosahedral capsid with a diameter of ~95 nm (for the main “body” of the virion, measured vertex to vertex), and is composed of three major (II, III, and IV) and five minor (IIIa, IVa2, VI, VIII, and IX) polypeptides (Berke, 2007; San Martin, 2012). Protein IV, more commonly known as fibre, forms trimers that project from the capsid surface at each of the 12 vertices, and is the viral protein predominantly responsible for interacting and binding to the cell surface through the coxsackie–adenovirus receptor (CAR) (Bergelson et al., 1997, 1998). For Ads, the fibre protein is 37 nm in length (Rugroek et al., 1990; van Raaij et al., 1995), thus increasing the overall size of the virus to about ~169 nm. Other human serotypes differ in the length of fibre and the cell surface proteins with which they interact, which can significantly influence the cell types that they preferentially infect (Havenaar et al., 2002). For example, the Ad35 fibre protein is only 13 nm in length (for an overall virion size of ~110 nm), and binds CD46 rather than CAR (Gaggero et al., 2003; Saban et al., 2005). The ability of Ad to infect is intimately tied to its ability to bind to the target cell. Cells with no or low levels of either the primary or secondary Ads receptors are transduced at a greatly reduced frequency (Goldman et al., 1996; Nalbantoglu et al., 1999). CAR is frequently developmentally downregulated, thus reducing Ad infection efficiency of mature tissues such as muscle and neurons (Ahn et al., 2008; Nalbantoglu et al., 1999). Indeed, numerous groups have improved Ad transduction of a variety of cell types and tissues through introducing protein motifs into the fibre protein that redirect attachment to cell surface receptors prevalent on most cells, such as a poly-lysine motif which allows Ad to bind heparan sulphate proteoglycans (Branson et al., 2004; Wickham et al., 1997).

The preferential accumulation of Ad in the liver of treated animals has meant that many of the gene therapy “successes” when using Ad in animal models involve transduction of the liver either to restore a functional deficiency to hepatocytes, or to use this organ as a protein production factory to produce large amounts of secreted protein (Brunetti-Pierri and Ng, 2011). Use of Ad for therapy in other tissues has not been as successful, for example, since Ad does not efficiently extracellular from vasculature (Su et al., 2002), localised injections are required for efficient delivery to skeletal muscle (Quintan et al., 1992), unlike adenovirus-associated virus-based vectors which can escape circulation and transduce into all muscle groups after systemic delivery (Gregorovic et al., 2004). Even after direct skeletal muscle injection, Ad remains relatively localised and does not disperse within the muscle (Meullenet et al., 2004; Quintan et al., 1992). Thus, improvements in Ad vector design are necessary to improve Ad utility for treating diseases of tissues other than liver.

In this study, we asked whether decreasing the overall size of the Ad vector, through substitution of the native Ad5 fibre with a chimeric fibre containing the shorter shaft region from Ads (37 versus 12 nm fibre, respectively) could enhance the ability of Ad to extravasate from the vasculature into surrounding tissues, or improve spread after direct injection in muscle. This reduction in fibre length results in a 30% decrease in the overall diameter of the virus. We also address whether addition of a pK motif on the knob domain of the shortened fibre, to redirect injection to more ubiquitous cell surface receptors, also enhanced vector distribution, relative to vector containing the wildtype Ad5 fibre protein.

Results and discussion

Rationale and viral constructs

Ad-based vectors have a poor ability to extravasate into surrounding tissue after systemic delivery and also a poor ability to disperse beyond the site of injection after localised delivery in most tissues. In part, the inability to spread is due to the relatively large size of the Ad virion, which for Ads is approximately 169 nm. For comparison, AAV6, which can effectively spread to all tissues following systemic delivery (Gregorovic et al., 2004), is ~25 nm in diameter. We therefore investigated whether reducing the overall size of the Ad vector, by decreasing the length of the fibre protein, could enhance its dispersion in mice. We generated an Ad vector containing the short Ads shaft region of fibre fused to the native Ad5 fibre knob domain (Shayakhmetov and Lieber, 2000), designated Ads5LacZ, which decreased the overall size of the virus by ~30% relative to a normal Ads-based vector (Ads5LacZ) (Fig. 1A). Since the natural receptor for Ad, CAR, is downregulated on many mature tissues, we also designed a derivative of Ads5LacZ which contained a poly-lysine motif in the HI loop of the knob domain.

Fig. 1. Adenovirus vectors used in this study. Panel A: wildtype Ads has a fibre length of ~37 nm which, together with the main virion size of 98 nm, provide an overall virion diameter of 169 nm. Substitution of the ADS shaft region for that of Ads reduces the length of fibre to ~12 nm, and reduces the overall virion diameter to 110 nm, or 30% smaller than Ads. Viruses are drawn to approximate scale. Panel B: all tissues are depicted with the main viral region 1 (E1) and E3, and encode the E1a, E1b, and E3a genes under the regulation of the human cytomegalovirus (CMV) immediate early enhancer/promoter and bovine growth hormone polyadenylation sequence (pA). Ads5Sp6lacZ also contains a poly-lysine motif within the HI loop of the knob domain of fibre. Panels C and D: virus particles (100) were loaded in SDS-PAGE loading buffer, separated by SDS-PAGE, and the amount of hexon (Panel C) and fibre (Panel D) was determined by immunoblot.
designated Ad5SpKlacZ. Attachment for this virus occurs through
binding to heparan sulphate proteoglycans which are present on
the surface of most cells. Ad5SpKlacZ is not ablated for binding to
CAR. All of these viruses are deleted of the Ad E1 and E3 regions,
and encode the Escherichia coli lacZ gene under regulation by the
human cytomegalovirus immediate early enhancer/promoter and
bovine growth hormone polyadenylation sequence (Fig. 1D). These
viruses were tested in tissue culture and mice for enhanced uptake
and dispersion to a number of specific tissues.

All three viruses grew well and gave a similar yield upon large
scale virus purification (data not shown). Since the viruses may
have different inherent ability to infect cells, including the 293 cell
lines typically used for virus titration, we quantified the amount of
virus by particle count and verified the accuracy of the particle
counts by analysing the same number of particles of each virus by
immunoblot. Similar signal intensity was obtained for each virus
(Fig. 1C). We also verified the size of the fibre protein for each of
these viruses (Fig. 1D).

Infection of cell lines in vitro

We next compared the ability of the viruses to infect several
different common cell lines derived from specific tissues: A549
(human lung adenocarcinoma), MN1 (rat motor neuron line), and
undifferentiated or differentiated C2C12 (mouse myoblasts). Cells
grown in 35-mm dishes were infected in triplicate with an MOI of
10, and cell lysates were assayed 24 h postinfection for β-gal activity
using a chemiluminescence assay. All viruses infected A549 cells with very high efficiency, and gave rise to β-gal activity
significantly above background (Fig. 2A), which is perhaps not
surprising given the high level of expression of CAR on these cells
(Hidaka et al., 1999). Substituting the long fibre shaft of Ad5 for the
short shaft of Ad9 reduced the infection efficiency of A549 cells by
about 10-fold, but addition of the pkn motif to the short-fibre virus
restored the infection level, as gauged by β-gal activity, to that of
native Ad5 fibre.

In the motor neuron-like MN1 cells, expression from all viruses
was equal and approximately 10-fold higher than background,
but the overall level of β-gal activity was approximately 10- to
100-fold lower than that observed in A549 cells (Fig. 2B). This
latter observation is consistent with the apparent developmental
down-regulation of CAR expression in spinal cord of mice (Hotta
et al., 2003) and with our previous data showing that Ad5 does not
infect MN1 cells well (Goulet et al., 2013b). Addition of the pkn
motif on the Ad5S knob did not enhance infection of MN1 cells.
Similar to A549 cells, viruses infected both undifferentiated and
differentiated C2C12 cells with very high efficiency, and cells
treated with the vector containing the native Ad fibre showed an
approximately 10-fold higher level of β-gal activity than the other
viruses (Fig. 2C and D).

Virus infection in vivo

To examine whether reducing the length of fibre protein, and
thus the overall size of the virus, enhanced extravasation into
surrounding tissue, we evaluated β-galactosidase expression in
liver (a site for high level uptake of virus, regardless of injection
route) and in TA muscle by chemiluminescence activity assay
(Fig. 3). We used three doses of virus: 5 × 10^11 VP/kg (low),
1 × 10^12 VP/kg (middle) and 5 × 10^12 VP/kg (high), and either IP

![Fig. 2. Analysis of transgene expression from Ad5SlacZ, Ad5SlacZ and Ad5SpKlacZ in tissue culture. A549 (Panel A), MN1 (Panel B) or undifferentiated (Panel C) or differentiated (Panel D) C2C12 cells in 35-mm dishes were infected at a multiplicity of infection (MOI) of 10 with Ad5SlacZ, Ad5SpKlacZ and Ad5SpKlacZ and 24 h later, crude protein extracts were prepared and assayed for β-gal activity using a commercial chemiluminescence assay. Data is shown as average and standard deviation of the mean (n=3). *p<0.05.]
or IV injection. As a control, we injected the TA muscle directly with the highest dose of the three viruses. The data shows that the viruses were capable of infecting muscle and gave rise to very high levels of β-galactosidase activity (Fig. 3A). Of note, when normalised to the amount of protein in the sample, after direct TA muscle injection, approximately 20% of the β-gal activity was detected in the liver (Fig. 3B), suggesting there is significant escape from the site of injection to the liver. IP injection of the three viruses led to only a modest increase in β-gal activity in the TA muscle at the highest virus dose (Fig. 3C), and a dose dependent increase in expression in the liver for Ad5SlacZ and Ad5LacZ (Fig. 3D). Interestingly, after IP injection, no liver expression was observed for Ad5SpKlacZ, regardless of dose, suggesting that the virus may efficiently and preferentially infect the peritoneum and is not available for injection elsewhere. IV injection of the viruses did not result in a significant increase in β-gal activity in the TA muscle, with the exception of the highest dose of Ad5LacZ (Fig. 3E). For all viruses, following IV injection there was a significant dose-dependent increase in β-gal activity in the liver of treated animals, with an approximately equal level of expression for all viruses (Fig. 3F).

We also examined β-gal expression by histochemistry in tissue sections of TA muscle after TA, IP or IV injection of the viruses (Fig. 4). Mice were injected with the highest dose of virus (5 × 10^{12} VP/kg), the tissue was isolated 24 h later, fixed, sectioned and stained for β-gal activity. For the TA muscle, representative images from the top, middle and bottom of the muscle are shown. Consistent with our chemiluminescence activity assays, we observed significant levels of β-gal activity after direct injection of the three viruses into the TA muscle, but very limited expression after IP or IV injection (Fig. 4). Thus, systemic delivery of either Ad vector containing wildtype fibre or a shortened fibre does not lead to enhanced transduction of muscle.

Dispersion of virus after TA muscle injection

We next examined whether a decrease in virus size resulted in improved dispersion throughout the muscle following TA
injection. To examine the kinetics of expression, mice were injected in the TA muscle with our highest dose of vector (5 x 10^{12} VP/kg), and expression assessed in muscle and liver at 1, 2, and 3 days post-injection. In the TA muscle, all viruses produced a level of β-gal activity approximately 100-fold above background, and expression was relatively stable over the 3-day time course (Fig. 5A). In contrast, β-gal activity in the liver was highest at day 1, and steadily declined by about 1 log over the next 2 days, with all three viruses showing a similar trend (Fig. 5B). This latter observation is consistent with previous studies that have shown a robust anti-Ad inflammatory response in liver, in part due to uptake and activation of liver Kupffer cells, leading to a dramatic reduction in viral genomes within the first 24 hpi, and a more gradual decline over the next several days (Lieber et al., 1997; Wolff et al., 1997; Wiegall et al., 1997).

Histological analysis of TA muscle sections from treated mice showed that all viruses resulted in a significant level of β-gal activity (Fig. 5C), with no significant difference in the per cent of the cross sectional area transduced by each virus (Table 1). These results suggest that reducing the size of the virus, through reduced fibre length, does not significantly alter dispersion of the virus in muscle after localised delivery.

Retrograde transport of Ad to the spinal cord after TA muscle injection is inefficient.

Studies in rats have shown that injection of muscle with Ad can lead to efficient retrograde transport of the virus to motor neuron cell bodies in the spinal cord (Sassoon et al. and Shine, 1996; Ghiade et al., 1995; Nakajima et al., 2001). Retrograde transport has also been observed for a number of different viral vectors including adeno-associated virus (Rockstad et al., 2011) and lentivirus (Hirano et al., 2013). To determine if our modified viruses demonstrated altered retrograde transport, we injected TA muscle with 5 x 10^{12} VP/kg of the various viruses in a solution containing Texas Red-dextran. Dextran is taken up by motor neurons, which would fluoresce red, and allow us to identify the appropriate region of the spinal cord for β-gal staining (Nance and Burns, 1990). Spinal cords from treated mice were sectioned until fluorescent motor neurons were visible (Fig. 5A), and the next adjacent section was stained with X-gal to visualise the efficiency of Ad transduction. As shown in Fig. 5B, we only observe sparse and sporadic expression of β-gal in motor neurons, regardless of virus identity. These results suggest that the efficiency of uptake and retrograde transport of Ad in mice is low, and is not improved by reduced fibre size or the presence of a hepatic sulphate proteoglycan binding region on the fibre knob. Given that Ad does not infect motor neuron-like cells in culture very efficiently (Fig. 5B), it is perhaps not surprising that the efficiency of uptake and transduction of motor neurons in vivo is low. An enhancement in motor neuron uptake may be achievable through introduction of peptide motifs into the Ad capsid that specifically target infection to neurons (Podolin et al., 2011; Terasima et al., 2009), but this has yet to be examined. Alternatively, canine adenovirus has shown an enhanced ability to infect neurons and undergo retrograde transport (Soudal et al., 2001), suggesting it may be more amenable for the treatment of diseases of the motor neuron such as spinal muscular atrophy or amyotrophic lateral sclerosis (Coulet et al., 2013a; San Sebastian et al., 2013).

In this study, we have examined whether reducing the size of the adenovirus vector, through reduction in the length of the fibre protein, could result in enhanced delivery and distribution to muscle after systemic delivery. In general, reduction in the size of the fibre protein, with or without a polypeptide motif to redirect virus binding to cell surface heparan sulphate proteoglycans, had little effect on enhancing muscle cell transduction following systemic or localised delivery. Previous studies have suggested that the Ad2 fibre protein, which is very similar to the Ad5 fibre protein, may naturally bend, which would effectively reduce the overall diameter of Ad5SlacZ to closer to that of Ad5SlacZ. The Ad2 and Ad5 fibre protein shaft region contains 22 β-repeats. The twenty-first repeat, located just before the knob domain, is a non-consensus repeat that may allow for a small degree of bending between knob and shaft (van Ras et al., 1999). More importantly, the third β-repeat is also non-consensus, and may provide significant flexibility to the fibre protein. In cryo-EM images, Ad5 fibre appears “knicked” in this approximate region (Chiu et al., 2001; Stewart et al., 1997). Replacing these flexible repeats with the corresponding regions of the more rigid fibre from Ad37 abolished infection suggesting that bending of fibre does occur naturally and is important for Ad5 infection (Wu et al., 2003). Molecular modelling showed that the fibre protein would need to bend at an angle of at least ~70° to allow proper alignment of the RID motif contained in penton protein with surface exposed integrins (Wu et al., 2003). If fibre is capable of folding back...
towards the body of the Ad virion at such an acute angle, it would reduce the distance that the Ad5 fibre protrudes from the main body of the Ad virion from 37 nm to only ~16 nm. Short fibre shaft proteins, such as that of Ad9 used in this study, are predicted to be rigid (Chiu et al., 2001). Thus, the effective difference in length of the short and long fibre proteins used in this study may not be dramatically different, which could contribute to the similar transduction profiles observed for these viruses.

Another factor that could contribute to the similar transduction efficiencies of Ad5lacZ and Ad5IacZ may be the impact of the negative charge conferred on the virion by the Ad5 hexon protein. As discussed by Shyakhmetov and Lieber (2000), the surface exposed hypervariable regions of hexon from Ad serotypes with naturally short fibre proteins tend to be neutral or positively charged (Crawford-Milkova and Schnurr, 1996), allowing for the relatively close apposition of the Ad virion and negatively-charged cell membrane. In contrast, the hypervariable regions on the Ad5 hexon have a strong negative charge that may act as a significant repulsive force when combined with the short fibre protein, compromising efficient infection of virus with the cell (Shyakhmetov and Lieber, 2000).

As others have also shown (Guo et al., 1996; Wor gall et al., 1997), we observed that regardless of the route of administration, Ad naturally preferentially accumulates in the liver, leading to high levels expression in this tissue. Many of the successes in preclinical studies using Ad-mediated gene transfer involve diseases of the liver or use the liver as a protein-production factory for secreted protein (Brunetti-Pierri and Ng, 2011). Ad vectors have a natural tropism for liver and can persist and express a transgene for greater than 7 years after a single IV injection in non-human primates (Brunetti-Pierri et al., 2013). However, as demonstrated in this study, use of Ad vectors to target gene expression to alternative tissues remains a challenging aspect of Ad vector development.

Materials and methods

Cell culture

All cell culture media and reagents were obtained from Invitrogen (Burlington, ON). 293 (Graham et al., 1977), 293N3S (Graham, 1987) and A549 (American Type Culture Collection) cells were grown in monolayer in minimum essential medium (MEM) supplemented with 2 mM Glutamax, 0.1 mg/ml streptomycin and 100 Unit/ml penicillin, and 10% foetal bovine serum (FBS). MN1 cells
Fig. 6. Inefficient retrograde transport of Ad vectors in motor neurons after TA muscle injection in mice. Mice were injected in the TA muscle with $5 \times 10^{12}$ VP/kg of Ad5LacZ, Ad5S5LacZ and Ad5S5pKlacZ in a solution containing 16 mg/ml Texas Red-conjugated Dextran. Spinal cords were removed 48 h post-injection, fixed, and longitudinal sections were collected until motor neurons were detected by immunofluorescence. The next sequential section was then stained for β-gal activity, and viewed using a Leica M80 microscope.

(Salazar-Grueso et al., 1991) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 10% FBS, 2 mM L-Glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin, and were a kind gift of Dr. Jocelyn Cote (University of Ottawa). C2C12 cells (Blax et al., 1985) were grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin, and confluent plates were switched to medium supplemented with 2% horse serum to induce differentiation. C2C12 cells were allowed to differentiate for 4 days before infection.

Generation and propagation of viruses

All of the viruses used in this study are deleted of the Ad5 early region 1 (E1) and E3 regions, and were generated and propagated using standard techniques (Ross and Parks, 2009). A plasmid containing an Ad5 genome encoding a modified fibre protein with the Ad29 shaft and Ad5 knob was obtained from Drs. Dmitry Shlayakhmetov and Andreie Lieber (University of Washington) (Shlayakhmetov and Lieber, 2005). The modified fibre gene was subcloned into an E1/E3-deleted Ad genomic plasmid, pP2014 (Christou and Parks, 2011; Poulin et al., 2010), and a cytomegalovirus immediate early enhancer/promoter-LacZ expression cassette (pCA38, (Addison et al., 1997)) was introduced to replace the E1-deletion, using Scel-mediated recombination (Chartier et al., 1996), as detailed previously (Willemsen, 2008), and designated Ad5S5lacZ. To introduce the poly-lysine motif into the H-I loop of the knob domain of the short fibre, a $8911/7911$ fragment containing part of the knob domain was first subcloned into psiZ2 (Promega). This plasmid was PCR amplified with the synthetic oligonucleotides 5'-ata gcc ggc aaa aag aca aag aag aag aag aag gga gca cca aat gta tac tct atg tca ttc tca tgc 3' and 5' taa ggc ggc aat gtt gtc tcc gtc tgt cgt tct aat gga aag gta 3', which prime in opposite directions along the plasmid, creating a linear molecule with compatible cohesive ends. Redamplication of the plasmid creates a molecule encoding a short fibre knob domain that has been changed from amino acids GTDTT-PSAY to GTDTT-AGKIKKKKIGA-PSAY. The modified fibre protein was recombined into P2P2014 to replace the native Ad5 fibre, and the CMV-lacZ expression cassette added to replace the E1-deletion, and designated Ad5S5pKlacZ. Recombination of pCA38 and pP2014 generated the control virus Ad5S5lacZ. Particle counts were used to determine the titre of the vector; an aliquot of virus was diluted in assay buffer (1 mM EDTA, 0.1 SDS), heated for 20 min at 65 °C, and the absorbance determined as 1 $\lambda_{560} = 1.1 \times 10^{12}$ particles.

Immunoblot analysis

To examine the level of incorporation of the modified fibre proteins, we assayed dilutions of the virus stock for hexon (loading control) and fibre signal by immunoblot. Viruses were diluted to $10^5$ viral particles in a total of 10 µl of PBS, and combined with equal volume of 2 x SDS/PAGE protein loading buffer (62.5 mM Tris HCl pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue, 5% β-mercaptoethanol). Samples were boiled for 5 min, and separated by electrophoresis on a 12% SDS-polyacrylamide gel. The separated proteins were transferred to a polyvinylidene difluoride membrane (Immobilon-P, Millipore) and the membrane was probed with an antibody raised against all Ad capsid proteins (ab6982, 1/10,000; Abcam) or fibre (MS-1027-P, 1/1000, NeoMarkers). Binding of the primary antibody was detected using a goat or mouse anti-rabbit secondary antibody conjugated to

130
horseradish peroxidase (BioRad) and visualized by chemiluminescence reaction (Thermo Scientific ECL western blotting substrate) and autoradiography.

**Infection assays in vitro**

Triplicate 35 mm dishes of A549, MN1, or undifferentiated or differentiated C2C12 were seeded at a density of 0.3 x 10^6 cells per dish. The next day cells were infected at an multiplicity of infection (MOI) of 10 with Ad5lacZ, Ad5lacZ or Ad5SpGalZ (or mock infected), except for one series of C2C12 cells, which was switched to differentiation medium (DMEM plus 2%HS), and infected after 4 days of differentiation. Crude protein extracts were prepared from the infected cells 24 h later by lyzing the cells with 175 μL of Lysis Solution (Applied Biosystems). The samples were centrifuged at 9000g for 2 min at room temperature (RT) and the supernatant collected and stored at −80°C. The samples were thawed and assayed for β-galactosidase (β-gal) activity using a commercial chemiluminescence assay (Galacto-star, Applied Biosystems) and a 20/20i luminometer (Turner Biosystems).

**In vivo injections and tissue harvest**

All animal experiments were approved by and performed according to the guidelines set by the Animal Research Ethics Board at the University of Ottawa (Ottawa, ON, Canada). Six to eight-week-old C57Bl/6 mice (Charles River) were injected intravenously (IV) through the tail vein or intraperitoneally (IP) with 100 μL virus or PBS, or anaesthetized with halothane, and injected with virus or PBS in a volume of 25-30 μL in both the right and left tibialis anterior (TA) muscles. Three viral concentrations were used: 5 x 10^{11} VP/kg (low), 1 x 10^{13} VP/kg (middle) and 5 x 10^{13} VP/kg (high). One, two or three days later (as indicated in the specific experiment described below), the mice were euthanized with 100 μL euthanyl (CDMV Inc., Quebec City, QC). For determining the level of β-galactosidase activity, liver and TA muscles from treated animals were removed and immediately frozen in liquid nitrogen and stored at −80°C until processed as described below. For immunochemistry, TA muscles and the spinal cord were removed and immediately incubated in 2% paraformaldehyde (PFA) for 1 h, washed 3 times with PBS, and then incubated in 30% sucrose in PBS for 24–72 h. Tissues were equilibrated in 50:50:30 sucrose/OCT (Tissue-Tek 4583, VWR) for 1–2 h on a rocking platform. Samples were embedded in the same 30% sucrose by flash freezing in liquid nitrogen and stored at −80°C until sectioning. The tissues were sectioned using a cryostat in transverse or longitudinal 12 μm sections, mounted on a glass slide, and stored at −20°C.

**β-galactosidase staining**

Tissue sections were hydrated in PBS for 1–2 min then fully submerged in X-gal stain (5 mM K₃Fe(CN)₆, 5 mM K₄Fe(CN)₆, 2 mM MgCl₂, 1 mg/ml 5-bromo-4-chloro-3-indolyβ-d-galactoside (X-gal) in PBS for 24 h at 37°C. Slides were washed in PBS for 1 min and covered with a glass cover slip in a 1:1 mixture of PBS and 30% glycerol. Quantification of the stained areas was performed using Image J (Wayne Rasband, Research Services Branch, National Institute of Mental Health, Bethesda, Maryland, USA). A colour intensity threshold was applied to determine the area of the muscle section showing X-gal staining, which is reported as the percentage of the total cross-sectional area of the muscle.

To examine the efficiency of retrograde transport to motor neurons after TA injection, mice were injected with 5 x 10^{12} VP/kg of Ad5lacZ, Ad5lacZ and Ad5SpGalZ in a solution containing 16 mg/ml Texas Red-conjugated 3000 MW Dextran. The Texas-Red-conjugated Dextran is taken up by the motor neuron terminals, and undergoes retrograde transport to mark the motor neuron cell body (Nance and Burns, 1990). Spinal cords were removed 48 h post-injection. Tissues were fixed as described above and longitudinal sections were collected until Texas Red-stained motor neurons were detected by immunofluorescence. The next sequential section was then stained for β-gal activity and viewed using a Leica M80 microscope.

**Chemiluminescent β-galactosidase assay**

The liver samples were processed as previously described (Parks et al., 1989). Briefly, the entire liver was homogenised in 1 ml of PBS using a Power Gen 125 (Fisher Scientific) at a speed of 5.5 for approximately 10 s. The samples were sonicated twice for 15 s on ice, with a 10 s rest period in between. Samples were centrifuged at 37,000 g for 5 min and the supernatant removed to a fresh tube. TA muscles were homogenised using a liquid nitrogen chilled-mortar and pestle. The ground muscle was transferred to a microtube and solubilized in 400 μl RIPA buffer (50 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% glycerol, 1% NP-40, and protease inhibitors). Both liver and TA muscle samples were heated in a 55°C water bath for 15 min (to inactivate endogenous β-gal activity), followed by a final centrifugation at 16,000g for 10 min. The supernatants were collected and assayed for β-gal activity using a commercial kit (Galacto-star, Applied Biosystems) and a 20/20i luminometer (Turner Biosystems). Data was normalised to the amount of protein in each sample, as determined by Bradford assay (BioRad).

**Statistical analysis**

SigmaStat 2.0 was used to determine statistical significance. All error bars represent standard deviation and the p-Value was set to 0.05.

**Acknowledgments**

We thank Kathy Poulin, Melissa Geoffroy, Kaila Campbell, Natacha Provost, Kristin Willenssen and Benoit Goules for technical assistance. We thank Dr. Justin Boyer and Chantal Mazeron for advice on mouse surgery. Research in the Parks laboratory is supported by grants from the Canadian Institutes of Health Research (CIHR) (MOP122554, MOP136828), the Canadian Foundation for Innovation (28974), and the National Sciences and Engineering Research Council (NSERC) (238824-2012). E.R.M. was supported by an Ontario Graduate Scholarship from the Ontario Provincial Government and a scholarship from the CIHR. R.K. is a recipient of a University Health Research Chair from the University of Ottawa.

**References**


Title: A reduction in the human adenovirus virion size through use of a shortened fibre protein does not enhance muscle transduction following systemic or localised delivery in mice

Author: Emily R. McFall, Lyndsay M. Murray, John A. Lunde, Bernard J. Jasmin, Rashmi Kothary, Robin J. Parks

Publication: Virology
Publisher: Elsevier
Date: November 2014
Copyright © 2014 The Authors. Published by Elsevier Inc.

Creative Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND)

This article is published under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND).
For non-commercial purposes you may distribute and copy the article and include it in a collective work (such as an anthology), provided you do not alter or modify the article, without permission from Elsevier. The original work must always be appropriately credited.

Permission is not required for this non-commercial use. For commercial use please continue to request permission via RightsLink.
SUMMARY OF QUALIFICATIONS

- Masters in Microbiology and Immunology
- Experienced in different laboratory environments
- Excellent time management, organization and multitasking skills honed through research experience
- Knowledgeable in Microsoft Office and literature searches

EDUCATION

Masters of Science, Microbiology and Immunology 2012 - 2014
University of Ottawa, Ontario

- Thesis title: “Exploring novel methods to achieve systemic delivery of SMN for treatment of spinal muscular atrophy”
- University of Ottawa Dean’s and Admission scholarships

Bachelor of Science, Honours in Biopharmaceutical Sciences - Genomics Option with CO-OP 2007 - 2012
University of Ottawa, Ontario

- Thesis title: “Glycosylation, cis interactions and light chain species origin regulate Ly49 NK receptor binding with class I MHC molecules”
- Graduated with honors: Summa Cum Laude
- University of Ottawa Dean’s honors and Admission scholarships

SKILLS

Research
- Practiced in animal care, breeding, injections, dissections, homogeneous of tissues, RNA purification, tissue sectioning and staining
- Experienced in RT, PCR, q-PCR, RT-PCR, melt curves and electrophoresis
- Proficient at tissue culture, sterile conditions, transformation, digestion, cloning and transfection
- Studied viral and exosome purifications
- Skillful in co-immunoprecipitations, western blot, flow cytometry, immunohistochemistry and ELISA
- Able to operate autoclave, luminometer, nanosight, nano-drop and pH meters
- Examined both human and murine serum samples and collected human DNA
- Capable of following lab procedures and writing formal scientific lab reports for subjects such as cell biology, molecular biochemistry, genetics, general chemistry and organic chemistry

Academic Training
- Educated in biochemistry, cell biology, genetics, microbiology, molecular biology, organic chemistry, plant biology, virology, metabolism, pharmacology and cellular physiology
- Studied immune cells and their function, various pathogens and their replication, protein formation, cellular organelles, organic mechanisms, muscle development, pharmokinetics, energy potentials, drug development and bioinformatics

Transferable
- Practiced both oral and written communication through various presentation methods
- Strong organization, time management, multi-tasking and problem-solving skills
- Knowledge of experimental design and project development
- Motivated learner
- Proven ability to work individually and as a team member
- Computer skills include Microsoft Office, Access and literature searches
## PROFESSIONAL EXPERIENCE

<table>
<thead>
<tr>
<th>Organization</th>
<th>Dates</th>
<th>Position Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ottawa Hospital Research Institute – Dr. Rashmi Kothary</td>
<td>July 2014 - present</td>
<td>Laboratory Research Assistant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Perform murine dissections at various ages and harvested diverse tissues</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Set-up breeding pairs and maintained several murine lines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Conducted both RNA and protein extractions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Practiced in Q-PCR</td>
</tr>
<tr>
<td>Ottawa Hospital Research Institute – Dr. Robin Parks</td>
<td>May 2012 – July 2014</td>
<td>Masters Student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Conducted <em>in vivo</em> studies involving several injection methods of purified virus followed by collection of diverse tissues</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Examined both human and murine serum samples</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Collected and purified viruses and exosomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Operated a nanosight to determine sizes of nanoparticles</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Gained time management and organization skills while managing multiple research projects</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Expanded knowledge of experimental design and project development</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Involved with the training of new laboratory members</td>
</tr>
<tr>
<td>Ottawa Hospital, General Campus – Dr. Andrew Makrigiannis</td>
<td>September 2011 – April 2012</td>
<td>Honors Student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Performed staining and flow cytometry experiments using various fluorophores</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Initiated cloning experiments to development new cell lines for future testing</td>
</tr>
<tr>
<td>Viral Vaccine Division, BGTD, Health Canada</td>
<td>May 2011 – August 2011</td>
<td>Laboratory Assistant - Co-op Student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Performed ELISA optimizations on three different Hepatitis protocols</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated inventory and created records of calibrated scientific equipment</td>
</tr>
<tr>
<td>Drug GMP Inspection Unit, HPFB, Health Canada</td>
<td>September 2010 – December 2010</td>
<td>Co-op student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Created tracking sheets for foreign drug manufacturing, packaging or testing sites and organized documents as per the pre-screening process</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Participated in meetings with the Drug GMP and other units</td>
</tr>
<tr>
<td>Spartan Bioscience</td>
<td>May 2010 – August 2010</td>
<td>Laboratory Research Assistant - Co-op Student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Collected human DNA samples from co-workers ensuring no contamination to performed PRC reactions and melt curves using a DX12 real-time PCR machine</td>
</tr>
<tr>
<td>University of Ottawa</td>
<td>January 2010 – April 2010</td>
<td>Laboratory Assistant – Co-op Student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Followed and developed experimental protocols involving bioreports and mer-lux while working under sterile conditions</td>
</tr>
<tr>
<td>MDS Nordion, Kanata, Ontario</td>
<td>May 2009 – August 2009</td>
<td>Safety and Environment – Summer Student</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Recorded radioactive and chemical inventory, located in radioactive and non-radioactive areas in the form of weekly updates and final audit reports</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Nuclear worker training – Radiation safety</td>
</tr>
</tbody>
</table>
Dosimetry Lab Technician – Summer Student

- Responsible for preparing dosimetry kits which included light sensitive film, Fricke, a mild acid used for radiation, and analyzing irradiated film and preparing reports for customers

SCHOLARSHIPS AND AWARDS

- Dean’s scholarship, University of Ottawa 2014
- BMI MSc Microbiology and Immunology Seminar Day, University of Ottawa 2014
- Syed Sattar Master Student Award, University of Ottawa 2014
- Sir Frederick Banting and Charles Best Canada Graduate Scholarship, CIHR 2013 - 2014
- Microbiology and Immunology Award of Excellence, University of Ottawa 2013
- BMI MSc Microbiology and Immunology Poster Day, University of Ottawa 2013
- Queen Elizabeth II graduate scholarships in science and technology, Ontario government (Declined) 2012 - 2013
- Ontario Graduate scholarship, Ontario government 2012 - 2013
- Outstanding Research Project by an Biopharmaceutical Sciences student, University of Ottawa 2012
- Industrial Undergraduate Student Research Award, NSERC 2010
- Dean’s Honours list, University of Ottawa 2007 - 2012

PUBLICATIONS


TRAINING

- National Institutional Animal User Training
- Laboratory and Bio-Safety Training
- Autoclave Operation and Safety Training
- Reliability Status security clearance
- WHIMS
- Health Canada Division 5 – Drugs for Clinical Trials Involving Human Subjects
- Ontario G Driver’s licence

ACTIVITIES AND ASSOCIATIONS

- Educational: French as a second language (Beginner level) 2013 - 2014
- Academic: BMI Graduate Student Association, OHRI Institution Rep 2012 - 2014
- Fundraising: Relay for Life – Canadian Cancer Society Ottawa Walk for Muscular Dystrophy 2012 – Present